cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0. We also have transcriptomic data from the tumor's immune microenvironment obtained via a bladder biopsy. Based on these molecular characteristics, could you provide guidance on whether the patient is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0. We also have transcriptomic data from the tumor's immune microenvironment obtained via a bladder biopsy. Based on these molecular characteristics, could you provide guidance on whether the patient is likely to respond to Atezolizumab therapy? Evaluate the tumor microenvironment's transcriptomic profile by focusing on gene expression related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Based on your findings, provide a detailed rationale regarding the likelihood that the patient will respond to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 1.0, and a transcriptomic profile obtained from a bladder biopsy of the tumor immune microenvironment, what is the predicted likelihood of response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 1.0, and a transcriptomic profile obtained from a bladder biopsy of the tumor immune microenvironment, what is the predicted likelihood of response to Atezolizumab therapy? Review the transcriptomic profile of the tumor microenvironment with an emphasis on gene expression associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use your findings to provide a clear explanation of how likely the patient is to respond to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I have a white female patient with bladder urothelial carcinoma. A transcriptomic profile of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 44.0. Based on these findings, do you anticipate that she would respond favorably to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. A transcriptomic profile of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 44.0. Based on these findings, do you anticipate that she would respond favorably to atezolizumab therapy? Examine the gene expression patterns in the tumor microenvironment, focusing on markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, based on these findings, provide an evidence-based assessment of the patient’s potential response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a white female with bladder urothelial carcinoma, given her tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 2.0, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female with bladder urothelial carcinoma, given her tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 2.0, what is the likelihood that she will respond to Atezolizumab therapy? Review the gene expression profile within the tumor microenvironment with a focus on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use this data to provide an evidence-based evaluation of the patient’s likely response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy yielding a tumor immune microenvironment transcriptomic profile. With a tumor mutational burden (TMB) of 8.0, how likely is it that he will benefit from Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a bladder biopsy yielding a tumor immune microenvironment transcriptomic profile. With a tumor mutational burden (TMB) of 8.0, how likely is it that he will benefit from Atezolizumab therapy? Examine the gene expression patterns in the tumor microenvironment, specifically assessing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use this information to develop an evidence-based prediction of the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"For a white female patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence that she would respond favorably to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is there evidence that she would respond favorably to atezolizumab therapy? Evaluate the gene expression profiles in the tumor microenvironment with a focus on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these data to formulate an evidence-based prediction regarding the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 11.0. Based on these findings, is it reasonable to expect a response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 11.0. Based on these findings, is it reasonable to expect a response to atezolizumab therapy? Assess the gene expression patterns within the tumor microenvironment, concentrating on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these data to generate an evidence-based prediction of the patient's likely response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 18.0, and we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 18.0, and we have a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. Based on these findings, is he likely to respond to Atezolizumab therapy? Evaluate the gene expression profiles within the tumor microenvironment, focusing specifically on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use this information to formulate an evidence-based prediction of the patient’s potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) was not determinable (nan). Given these findings, how would you assess her likelihood of responding to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) was not determinable (nan). Given these findings, how would you assess her likelihood of responding to Atezolizumab therapy? Examine the gene expression patterns in the tumor microenvironment, with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use these findings to develop an evidence-based prediction regarding the patient’s potential treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, where we have obtained a transcriptomic profile of the tumor immune microenvironment via a nanobiopsy and his tumor mutation burden (TMB) is reported as not available, what is the likelihood that he will respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, where we have obtained a transcriptomic profile of the tumor immune microenvironment via a nanobiopsy and his tumor mutation burden (TMB) is reported as not available, what is the likelihood that he will respond to Atezolizumab therapy? Review the gene expression profiles within the tumor microenvironment, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use this data to make an evidence-based assessment of the patient’s likely response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how likely is it that he will respond to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, how likely is it that he will respond to atezolizumab therapy? Examine the gene expression profiles observed within the tumor microenvironment, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use the findings from this analysis to guide an evidence-based evaluation of the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma and exhibiting a TMB of 8.0, can the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy provide insight into his potential response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma and exhibiting a TMB of 8.0, can the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy provide insight into his potential response to Atezolizumab therapy? Review the gene expression data from the tumor microenvironment with particular attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use these results to inform an evidence-based assessment of the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"In a Caucasian female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutation burden data is not available. How likely is this patient to respond to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutation burden data is not available. How likely is this patient to respond to Atezolizumab therapy? Review the tumor microenvironment's gene expression data with an emphasis on identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, apply these findings to make an evidence-based evaluation of the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. With a tumor mutation burden of 9.0, what is the likelihood that he will respond favorably to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) and have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. With a tumor mutation burden of 9.0, what is the likelihood that he will respond favorably to atezolizumab therapy? Examine the gene expression data from the tumor microenvironment, focusing on identifying markers that indicate the presence of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these findings to form an evidence-based assessment of the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"My White female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy and a tumor mutation burden of 4.0. Based on these findings, is she likely to benefit from Atezolizumab therapy?","My White female patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy and a tumor mutation burden of 4.0. Based on these findings, is she likely to benefit from Atezolizumab therapy? Review the gene expression profile from the tumor microenvironment, with a focus on detecting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these results to support a data-driven evaluation of the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 32.0, does the transcriptomic profile of the tumor immune microenvironment from his ureter biopsy suggest a likely positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 32.0, does the transcriptomic profile of the tumor immune microenvironment from his ureter biopsy suggest a likely positive response to Atezolizumab therapy? Examine the gene expression data from the patient’s tumor microenvironment with a particular focus on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these findings to guide an evidence-based evaluation of the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"For a Caucasian male with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by transcriptomic profiling from a bladder biopsy and who has a tumor mutational burden of 21.0, would you expect a favorable response to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized by transcriptomic profiling from a bladder biopsy and who has a tumor mutational burden of 21.0, would you expect a favorable response to Atezolizumab therapy? Review the tumor microenvironment's gene expression profile, specifically focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use this information to conduct a thorough, evidence-based assessment of the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized via transcriptomic analysis from a kidney biopsy and who has a tumor mutation burden of 10.0, what is the likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized via transcriptomic analysis from a kidney biopsy and who has a tumor mutation burden of 10.0, what is the likelihood of a positive response to atezolizumab therapy? Review the gene expression profile within the tumor microenvironment with special attention to markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Utilize these findings to perform a detailed, evidence-based evaluation of the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"In a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 38. Would you expect that he is likely to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 38. Would you expect that he is likely to respond to Atezolizumab therapy? Examine the tumor microenvironment's gene expression profile with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use the results of this analysis to conduct a detailed, evidence-based evaluation of the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 7.0. Given her transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, would she be a good candidate for Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 7.0. Given her transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, would she be a good candidate for Atezolizumab therapy? Review the tumor microenvironment’s gene expression profile, specifically focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, use these findings to perform an evidence-based assessment of the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For our Caucasian patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For our Caucasian patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Examine the gene expression profile of the tumor microenvironment with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, apply these results to conduct an evidence-based evaluation of the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 15.0. We also have transcriptomic data from a bladder biopsy focused on the tumor immune microenvironment. Based on these findings, can we expect a positive response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 15.0. We also have transcriptomic data from a bladder biopsy focused on the tumor immune microenvironment. Based on these findings, can we expect a positive response to Atezolizumab therapy? Review the gene expression profile within the tumor microenvironment, specifically evaluating markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these findings to perform an evidence-based assessment of the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden value is not available. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden value is not available. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy? Examine the gene expression profile from the tumor microenvironment, paying close attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these findings to guide an evidence-based evaluation of the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a lung biopsy, and his tumor mutation burden is not available. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a lung biopsy, and his tumor mutation burden is not available. Given these findings, what is the likelihood that he will respond to Atezolizumab therapy? Review the gene expression data from the tumor microenvironment, specifically assessing markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these results to inform an evidence-based assessment of the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest a favorable response to atezolizumab therapy? Examine the gene expression data from the tumor microenvironment, focusing on markers characteristic of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Use these findings to conduct an evidence-based evaluation of the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"A 65-year-old African American male with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 7.0 and a detailed transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy. Based on these findings, can we expect a favorable response to atezolizumab therapy?","A 65-year-old African American male with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 7.0 and a detailed transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy. Based on these findings, can we expect a favorable response to atezolizumab therapy? Review the gene expression profile obtained from the tumor microenvironment. Focus on markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these findings to assess the patient's therapeutic response based on current evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"We have a  white male patient with bladder urothelial carcinoma. His tumor transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 19.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","We have a  white male patient with bladder urothelial carcinoma. His tumor transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 19.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Analyze the gene expression data from the tumor microenvironment, with particular emphasis on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, synthesize these observations alongside current clinical evidence to evaluate the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, is it anticipated that the patient will respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, is it anticipated that the patient will respond favorably to atezolizumab therapy? Review the gene expression data from the tumor microenvironment, focusing on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these findings with the latest clinical evidence to assess the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma. We have performed transcriptomic profiling on the tumor immune microenvironment from his bladder biopsy, and his tumor mutational burden is 5.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma. We have performed transcriptomic profiling on the tumor immune microenvironment from his bladder biopsy, and his tumor mutational burden is 5.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Examine the gene expression profile from the tumor microenvironment, specifically evaluating markers that indicate exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with current clinical evidence to determine the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a TMB of 8.0, what is the anticipated response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a TMB of 8.0, what is the anticipated response to Atezolizumab therapy? Review the gene expression data from the tumor microenvironment with a focus on markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular results with the latest clinical evidence to evaluate the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 13.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a ureter biopsy, would Atezolizumab therapy be an appropriate treatment option?","In a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 13.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a ureter biopsy, would Atezolizumab therapy be an appropriate treatment option? Examine the gene expression data from the tumor microenvironment, paying special attention to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with current clinical evidence to assess the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 16.0. We also have a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy. Based on these findings, what is his potential likelihood of responding to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 16.0. We also have a transcriptomic profile of his tumor immune microenvironment obtained from a kidney biopsy. Based on these findings, what is his potential likelihood of responding to atezolizumab therapy? Review the gene expression profile from the tumor microenvironment, with a focus on markers identifying exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular observations with up-to-date clinical evidence to evaluate the patient's therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 and for whom we have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there an expectation of a favorable response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 and for whom we have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, is there an expectation of a favorable response to atezolizumab therapy? Examine the tumor microenvironment's gene expression profile, specifically identifying markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with current clinical evidence to assess the patient's response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"My white female patient has bladder urothelial carcinoma, and we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. However, the tumor mutation burden (TMB) is not available. Based on these data, can we predict her likely response to Atezolizumab therapy?","My white female patient has bladder urothelial carcinoma, and we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. However, the tumor mutation burden (TMB) is not available. Based on these data, can we predict her likely response to Atezolizumab therapy? Review the gene expression profile of the tumor microenvironment and specifically identify markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, compare these molecular findings with current clinical evidence to evaluate the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"For a White male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 7.0, whose tumor immune microenvironment transcriptomic profile is available from a bladder biopsy, is there evidence suggesting a likely response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 7.0, whose tumor immune microenvironment transcriptomic profile is available from a bladder biopsy, is there evidence suggesting a likely response to Atezolizumab therapy? Examine the gene expression profile of the tumor microenvironment, focusing on markers that indicate exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, compare these molecular findings with the latest clinical evidence to determine the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, the tumor biopsy shows a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 20.0. Based on these findings, can we expect a response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, the tumor biopsy shows a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 20.0. Based on these findings, can we expect a response to Atezolizumab therapy? Review the gene expression patterns in the tumor microenvironment, specifically analyzing markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the most current clinical data to assess the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, and her tumor mutation burden is 5.0. Based on these findings, is she likely to respond to atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, and her tumor mutation burden is 5.0. Based on these findings, is she likely to respond to atezolizumab therapy? Examine the gene expression profiles within the tumor microenvironment, focusing on markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular findings with the latest clinical data to evaluate the patient’s response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 38.0, is there evidence to suggest that he would benefit from Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 38.0, is there evidence to suggest that he would benefit from Atezolizumab therapy? Review the gene expression patterns in the tumor microenvironment, specifically targeting markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with current clinical data to assess the patient’s therapeutic response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"In a white male patient with bladder urothelial carcinoma presenting a tumor mutation burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, can we expect a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma presenting a tumor mutation burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, can we expect a favorable response to Atezolizumab therapy? Examine the gene expression profile of the tumor microenvironment, focusing on markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical data to assess their response to current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and whose tumor immune microenvironment has been profiled via transcriptomics from a bladder biopsy, what is the likelihood of response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and whose tumor immune microenvironment has been profiled via transcriptomics from a bladder biopsy, what is the likelihood of response to Atezolizumab therapy? Assess the tumor microenvironment’s gene expression, concentrating on markers that indicate exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical information to determine how well they are responding to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"Given a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic data of the tumor immune microenvironment shows a tumor mutational burden of 13.0, would he be likely to respond to atezolizumab therapy?","Given a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic data of the tumor immune microenvironment shows a tumor mutational burden of 13.0, would he be likely to respond to atezolizumab therapy? Evaluate the gene expression within the tumor microenvironment by focusing on markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, compare these molecular findings with the patient’s clinical data to assess their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Based on a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden of 5.0, is it likely that the patient will respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Based on a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden of 5.0, is it likely that the patient will respond to atezolizumab therapy? Assess the gene expression within the tumor microenvironment by targeting markers that identify exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular insights with the patient’s clinical data to evaluate their response to the treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For my white female patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy shows a transcriptomic profile of the immune microenvironment and a TMB of 5.0, what is the likelihood that she will respond to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy shows a transcriptomic profile of the immune microenvironment and a TMB of 5.0, what is the likelihood that she will respond to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring the expression of genes associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical information to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"My White female patient with bladder urothelial carcinoma has a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy?","My White female patient with bladder urothelial carcinoma has a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy? Assess the tumor microenvironment by quantifying the expression levels of genes linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular results with the patient’s clinical data to evaluate their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"I have a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomics from a previous biopsy, but the tumor mutation burden (TMB) is not available. Based on these findings, what is the likelihood of response to atezolizumab therapy?","I have a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomics from a previous biopsy, but the tumor mutation burden (TMB) is not available. Based on these findings, what is the likelihood of response to atezolizumab therapy? Evaluate the tumor microenvironment by measuring the expression levels of genes associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have these molecular data, compare them with the patient’s clinical profile to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 12.0, how predictive is the transcriptomic profile from a lymph node biopsy of the tumor immune microenvironment regarding a favorable response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 12.0, how predictive is the transcriptomic profile from a lymph node biopsy of the tumor immune microenvironment regarding a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying the gene expression levels indicative of exhausted and cytotoxic T cells, as well as monocytes and macrophages. Then, integrate these molecular findings with the patient’s clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"In an Asian male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy was obtained and the tumor mutational burden (TMB) is 1.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy was obtained and the tumor mutational burden (TMB) is 1.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression markers associated with exhausted and cytotoxic T cells, as well as indicators for monocytes and macrophages. Then, combine these molecular findings with the patient’s clinical information to accurately assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"Our patient, a Caucasian male diagnosed with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 6.0 mutations/Mb. Based on these findings, how likely is he to respond to atezolizumab therapy?","Our patient, a Caucasian male diagnosed with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 6.0 mutations/Mb. Based on these findings, how likely is he to respond to atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression markers for exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages. Then, integrate these molecular findings with the patient’s clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"For a patient with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, does the current evidence suggest a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, does the current evidence suggest a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression markers specific to exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages. Then, correlate these molecular findings with the patient’s clinical data to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"In a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of response to Atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels for markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient's clinical data to evaluate their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 22.0. His biopsy provided a transcriptomic profile of the tumor's immune microenvironment. Based on these findings, is there evidence to suggest that he will respond favorably to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 22.0. His biopsy provided a transcriptomic profile of the tumor's immune microenvironment. Based on these findings, is there evidence to suggest that he will respond favorably to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression of markers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular assessments with the patient's clinical profile to determine their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 1.0, what evidence supports the likelihood of a response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 1.0, what evidence supports the likelihood of a response to Atezolizumab therapy? Assess the tumor microenvironment by measuring the gene expression levels of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient's clinical data to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"We have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a ureter biopsy, but her tumor mutational burden data is not available. Based on these findings, is she a suitable candidate for Atezolizumab therapy?","We have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a ureter biopsy, but her tumor mutational burden data is not available. Based on these findings, is she a suitable candidate for Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical data to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 2.0 mutations/Mb. Based on these findings, would you expect the patient to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 2.0 mutations/Mb. Based on these findings, would you expect the patient to respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring the gene expression of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical information to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy. The tumor mutational burden (TMB) is 11.0. In this context, is it likely that the patient will respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy. The tumor mutational burden (TMB) is 11.0. In this context, is it likely that the patient will respond favorably to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, combine these molecular results with the patient's clinical data to comprehensively assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 9.0 and available transcriptomic data from a bladder biopsy, can we predict a response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 9.0 and available transcriptomic data from a bladder biopsy, can we predict a response to Atezolizumab therapy? Assess the tumor microenvironment by measuring the gene expression levels of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient's clinical data to thoroughly evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled transcriptomically from a kidney biopsy. The tumor mutational burden (TMB) is not available. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled transcriptomically from a kidney biopsy. The tumor mutational burden (TMB) is not available. Based on these findings, can we expect a favorable response to atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular results with the patient's clinical data to provide a comprehensive assessment of their response to the current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For a White male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 14.0 and available transcriptomic data of his tumor immune microenvironment from a kidney biopsy, how likely is he to respond to atezolizumab therapy?","For a White male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 14.0 and available transcriptomic data of his tumor immune microenvironment from a kidney biopsy, how likely is he to respond to atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels for markers corresponding to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical data to perform a thorough evaluation of their response to the current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 18.0. How might these findings inform the likelihood of a positive response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 18.0. How might these findings inform the likelihood of a positive response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient's clinical information to comprehensively assess their response to the current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"My Caucasian patient has bladder urothelial carcinoma, and a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden of 13.0. Based on these findings, is it likely that the patient would respond to atezolizumab therapy?","My Caucasian patient has bladder urothelial carcinoma, and a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden of 13.0. Based on these findings, is it likely that the patient would respond to atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient's clinical data to thoroughly evaluate their response to the current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"In a Black/African American female patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden of 8.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy?","In a Black/African American female patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden of 8.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Integrate these molecular findings with the patient’s clinical data to comprehensively assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"I am evaluating a white female patient with bladder urothelial carcinoma. The tumor biopsy's transcriptomic analysis of the immune microenvironment shows a tumor mutation burden of 6.0 mutations per megabase. Given this molecular profile, what is the likelihood that she will respond to Atezolizumab therapy?","I am evaluating a white female patient with bladder urothelial carcinoma. The tumor biopsy's transcriptomic analysis of the immune microenvironment shows a tumor mutation burden of 6.0 mutations per megabase. Given this molecular profile, what is the likelihood that she will respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring the expression levels of genes that serve as markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient's clinical information to provide a thorough evaluation of their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"For a White male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for transcriptomic profiling of his tumor immune microenvironment and has a tumor mutation burden reported as 'nan', based on these data, what is his likelihood of responding to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma who has undergone a bladder biopsy for transcriptomic profiling of his tumor immune microenvironment and has a tumor mutation burden reported as 'nan', based on these data, what is his likelihood of responding to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular data with the patient's clinical profile to comprehensively assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For our Caucasian patient with bladder urothelial carcinoma, the tumor mutational burden is 23.0 and we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy?","For our Caucasian patient with bladder urothelial carcinoma, the tumor mutational burden is 23.0 and we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, is the patient likely to respond to atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression markers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient’s clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"My Caucasian female patient has been diagnosed with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy, but her tumor mutational burden (TMB) result is reported as ""nan."" Based on these findings, do you anticipate that she would respond to Atezolizumab therapy?","My Caucasian female patient has been diagnosed with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy, but her tumor mutational burden (TMB) result is reported as ""nan."" Based on these findings, do you anticipate that she would respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical information to determine how effectively they are responding to their current treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a tumor mutation burden of 2.0 mutations/Mb, should I expect a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a tumor mutation burden of 2.0 mutations/Mb, should I expect a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels of markers that distinguish exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, combine these molecular data with the patient’s clinical profile to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"I am managing a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on these data, what can be inferred about his potential response to atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutational burden is not available. Based on these data, what can be inferred about his potential response to atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression for markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these findings with the patient's clinical profile to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"Given my white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden of 7.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is his likelihood of responding to Atezolizumab therapy?","Given my white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden of 7.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is his likelihood of responding to Atezolizumab therapy? Analyze the tumor microenvironment by measuring the gene expression levels of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"I have an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile reveals a tumor mutation burden of 1.0. Based on this data, what is the likelihood that he would respond to Atezolizumab therapy?","I have an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile reveals a tumor mutation burden of 1.0. Based on this data, what is the likelihood that he would respond to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring gene expression levels for markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical information to assess the response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has a ureter biopsy showing a tumor immune microenvironment transcriptomic profile with a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a ureter biopsy showing a tumor immune microenvironment transcriptomic profile with a tumor mutational burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Assess the tumor microenvironment by quantifying gene expression for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular data with the patient’s clinical profile to determine how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained via bladder biopsy and who has a tumor mutational burden (TMB) of 5.0, how likely is it that atezolizumab therapy would be effective?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained via bladder biopsy and who has a tumor mutational burden (TMB) of 5.0, how likely is it that atezolizumab therapy would be effective? Evaluate the tumor microenvironment by measuring the gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular findings with the patient's clinical information to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, how does a transcriptomic profile of his tumor immune microenvironment paired with a tumor mutational burden of 6.0 inform the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, how does a transcriptomic profile of his tumor immune microenvironment paired with a tumor mutational burden of 6.0 inform the likelihood of a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying the gene expression of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient's clinical data to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via lung biopsy and with a reported tumor mutation burden that is unavailable, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via lung biopsy and with a reported tumor mutation burden that is unavailable, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression levels for markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical information to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"My white male patient has bladder urothelial carcinoma, and a lymph node biopsy of his tumor immune microenvironment yielded a transcriptomic profile showing a tumor mutational burden of 2.0 mutations/megabase. Based on these findings, is he likely to respond to Atezolizumab therapy?","My white male patient has bladder urothelial carcinoma, and a lymph node biopsy of his tumor immune microenvironment yielded a transcriptomic profile showing a tumor mutational burden of 2.0 mutations/megabase. Based on these findings, is he likely to respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring the expression levels of genes linked to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular data with the patient’s clinical profile to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 44.0. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 44.0. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression associated with markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient's clinical data to determine their response to the existing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected response to Atezolizumab therapy? Assess the tumor microenvironment by measuring the expression levels of genes corresponding to markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular results with the patient’s clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"In a Caucasian male patient with bladder urothelial carcinoma, we performed a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy, which revealed a tumor mutation burden of 17.0. Based on these findings, is the patient likely to respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, we performed a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy, which revealed a tumor mutation burden of 17.0. Based on these findings, is the patient likely to respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient's clinical data to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I have a White male patient with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 11.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 11.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring the gene expression levels of markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient's clinical data to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutational burden is not available (marked as ""nan""). Considering this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutational burden is not available (marked as ""nan""). Considering this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient’s clinical information to determine their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"We have a white male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. However, his tumor mutational burden (TMB) is not available. Based on these findings, would you expect him to respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. However, his tumor mutational burden (TMB) is not available. Based on these findings, would you expect him to respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels for markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, integrate these molecular data with the patient’s clinical profile to evaluate their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, how does a tumor mutational burden (TMB) of 12, in conjunction with a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, inform predictions regarding his likely response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, how does a tumor mutational burden (TMB) of 12, in conjunction with a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, inform predictions regarding his likely response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression of markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient’s clinical data to assess their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have a white male patient with bladder urothelial carcinoma who has undergone a bladder biopsy, providing a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden of 6.0, can we predict whether he is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has undergone a bladder biopsy, providing a transcriptomic profile of the tumor immune microenvironment. With a tumor mutational burden of 6.0, can we predict whether he is likely to respond to Atezolizumab therapy? Assess the tumor microenvironment by quantifying the gene expression levels of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical information to evaluate their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"In a Caucasian patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and the TMB is 5.0, how likely is a favorable response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and the TMB is 5.0, how likely is a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring the gene expression levels of markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Next, combine these molecular findings with the patient’s clinical information to determine their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,For my white male patient with bladder urothelial carcinoma—whose tumor immune microenvironment has been profiled via nanobiopsy and who has a tumor mutational burden of 8.0—what is the likelihood that he will respond favorably to Atezolizumab therapy?,"For my white male patient with bladder urothelial carcinoma—whose tumor immune microenvironment has been profiled via nanobiopsy and who has a tumor mutational burden of 8.0—what is the likelihood that he will respond favorably to Atezolizumab therapy? Assess the tumor microenvironment by quantifying the gene expression of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical history to evaluate their response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"In our Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 8.0. Based on these findings, would you consider Atezolizumab to be an effective treatment option?","In our Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 8.0. Based on these findings, would you consider Atezolizumab to be an effective treatment option? Evaluate the tumor microenvironment by measuring the gene expression levels of markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical history to determine their treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a patient with bladder urothelial carcinoma with unknown M status, whose tumor immune microenvironment has been profiled via bladder biopsy and with a tumor mutational burden of 0, what is the anticipated response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma with unknown M status, whose tumor immune microenvironment has been profiled via bladder biopsy and with a tumor mutational burden of 0, what is the anticipated response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying gene expression of markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular data with the patient’s clinical history to evaluate their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"I have a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0. We obtained transcriptomic data from a kidney biopsy of his tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0. We obtained transcriptomic data from a kidney biopsy of his tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Evaluate the tumor microenvironment by measuring the gene expression levels of markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical history to assess their response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma has had transcriptomic profiling of the tumor immune microenvironment obtained via kidney biopsy, and his tumor mutational burden is 6.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has had transcriptomic profiling of the tumor immune microenvironment obtained via kidney biopsy, and his tumor mutational burden is 6.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy? Assess the tumor microenvironment by quantifying the gene expression of markers linked to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular results with the patient’s clinical history to determine their response to the treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA), for whom a transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and the tumor mutational burden is unavailable, what predictive insights can we derive regarding her likely response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA), for whom a transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and the tumor mutational burden is unavailable, what predictive insights can we derive regarding her likely response to Atezolizumab therapy? Review the tumor microenvironment by quantitatively measuring gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these results with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a ureter biopsy showing a tumor mutation burden (TMB) of 59.0. Based on this data, is it likely that the patient would respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a ureter biopsy showing a tumor mutation burden (TMB) of 59.0. Based on this data, is it likely that the patient would respond to atezolizumab therapy? Evaluate the tumor microenvironment by quantitatively assessing gene expression markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular findings with the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, would treatment with atezolizumab likely result in a clinical response?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, would treatment with atezolizumab likely result in a clinical response? Assess the tumor microenvironment by measuring gene expression levels for markers of exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"In a bladder urothelial carcinoma patient who has undergone a ureter biopsy with transcriptomic profiling of the tumor immune microenvironment and exhibits a tumor mutation burden of 12.0, would you expect a favorable response to Atezolizumab therapy?","In a bladder urothelial carcinoma patient who has undergone a ureter biopsy with transcriptomic profiling of the tumor immune microenvironment and exhibits a tumor mutation burden of 12.0, would you expect a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, and his tumor mutational burden (TMB) is 4.0. Based on these findings, what is the likelihood of response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, and his tumor mutational burden (TMB) is 4.0. Based on these findings, what is the likelihood of response to Atezolizumab therapy? Please assess the tumor microenvironment by accurately quantifying gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Once you have this molecular profile, integrate it with the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"My white male patient with bladder urothelial carcinoma has a tumor mutation burden of 11 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","My white male patient with bladder urothelial carcinoma has a tumor mutation burden of 11 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Evaluate the tumor microenvironment by quantifying the gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate this molecular profile with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. His tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. His tumor immune microenvironment has been profiled transcriptomically from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, is he likely to benefit from Atezolizumab therapy? Review the tumor microenvironment by quantifying gene expression markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient's clinical history to evaluate their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and an indeterminate tumor mutation burden (TMB), how likely is it that she will respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and an indeterminate tumor mutation burden (TMB), how likely is it that she will respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression markers that correspond to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical history to determine how well they are responding to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy, and his tumor mutational burden (TMB) is 5.0. Based on these findings, would you expect Atezolizumab therapy to be effective?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy, and his tumor mutational burden (TMB) is 5.0. Based on these findings, would you expect Atezolizumab therapy to be effective? Evaluate the tumor microenvironment by quantifying gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, combine these molecular findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a Native Hawaiian/Pacific Islander patient with bladder urothelial carcinoma, we have transcriptomic profiling data of the tumor immune microenvironment from a previous biopsy and a tumor mutational burden of 19.0 mutations/Mb. Based on this information, what is the likelihood that the patient would respond to Atezolizumab therapy?","For a Native Hawaiian/Pacific Islander patient with bladder urothelial carcinoma, we have transcriptomic profiling data of the tumor immune microenvironment from a previous biopsy and a tumor mutational burden of 19.0 mutations/Mb. Based on this information, what is the likelihood that the patient would respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, where the transcriptomic profile of the tumor immune microenvironment is available but the tumor mutational burden is not quantified, what is the likelihood that he will respond favorably to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, where the transcriptomic profile of the tumor immune microenvironment is available but the tumor mutational burden is not quantified, what is the likelihood that he will respond favorably to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying gene expression for markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, correlate these molecular findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor's immune microenvironment from a bladder biopsy, but her tumor mutation burden (TMB) is not available. Based on the available data, is there evidence to suggest that she would respond favorably to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. We have obtained a transcriptomic profile of her tumor's immune microenvironment from a bladder biopsy, but her tumor mutation burden (TMB) is not available. Based on the available data, is there evidence to suggest that she would respond favorably to Atezolizumab therapy? Assess the tumor microenvironment by quantitatively measuring the gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages. Then, integrate these molecular data with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 33.0 and transcriptomic profiling data of the tumor immune microenvironment obtained via kidney biopsy. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 33.0 and transcriptomic profiling data of the tumor immune microenvironment obtained via kidney biopsy. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Quantitatively measure gene expression levels of markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Then, correlate these molecular results with the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"I have a white male patient with bladder urothelial carcinoma who presents with a high tumor mutational burden (32.0) and has a transcriptomic profile of the tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who presents with a high tumor mutational burden (32.0) and has a transcriptomic profile of the tumor immune microenvironment from a previous biopsy. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Measure the expression levels of genes that serve as markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Next, compare these molecular findings with the patient’s clinical history to assess how they are responding to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 2.0, can we predict whether he is likely to respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 2.0, can we predict whether he is likely to respond to Atezolizumab therapy? Quantitatively assess the expression of gene markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Then, integrate these molecular findings with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"For a patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment and tumor mutation burden (TMB) of 14.0 are available, could these data help predict a favorable response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment and tumor mutation burden (TMB) of 14.0 are available, could these data help predict a favorable response to atezolizumab therapy? Perform a quantitative analysis of gene markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages in the tumor microenvironment. Then, correlate these molecular findings with the patient's clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"Does the transcriptomic profile of the tumor immune microenvironment obtained via nan biopsy, along with a reported TMB of nan, support the likelihood that this white male patient with bladder urothelial carcinoma will respond to atezolizumab therapy?","Does the transcriptomic profile of the tumor immune microenvironment obtained via nan biopsy, along with a reported TMB of nan, support the likelihood that this white male patient with bladder urothelial carcinoma will respond to atezolizumab therapy? Conduct a detailed quantitative evaluation of gene markers related to exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Following this analysis, integrate the molecular data with the patient's clinical history to determine their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma, a TMB of 9.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, would you anticipate a favorable therapeutic response to Atezolizumab?","For a Caucasian patient with bladder urothelial carcinoma, a TMB of 9.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, would you anticipate a favorable therapeutic response to Atezolizumab? Perform a comprehensive quantitative analysis of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Then, correlate these molecular findings with the patient's clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"I have an Asian female patient with bladder urothelial carcinoma who has a transcriptomic profile from a ureter biopsy, and her tumor mutational burden (TMB) is 12.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","I have an Asian female patient with bladder urothelial carcinoma who has a transcriptomic profile from a ureter biopsy, and her tumor mutational burden (TMB) is 12.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? Please conduct a detailed quantitative assessment of the gene expression markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages in the tumor microenvironment. After completing this analysis, integrate the molecular results with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutation burden (TMB) is unavailable. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). We obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, but his tumor mutation burden (TMB) is unavailable. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Perform a comprehensive quantitative analysis of gene expression markers that are indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages in the tumor microenvironment. Once you have these molecular results, please integrate them with the patient’s clinical history to assess how well the patient is responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and transcriptomic profiling data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 and transcriptomic profiling data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy? Conduct a thorough quantitative analysis of gene expression for markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Once these molecular data have been obtained, integrate them with the patient’s clinical history to evaluate the patient’s response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"In a white male patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a liver biopsy and a tumor mutational burden of 10.0, what is the likelihood that he will benefit from atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, given a transcriptomic profile of the tumor immune microenvironment from a liver biopsy and a tumor mutational burden of 10.0, what is the likelihood that he will benefit from atezolizumab therapy? Please perform a detailed quantitative evaluation of gene expression for markers indicative of exhausted T cells, cytotoxic T cells, monocytes, and macrophages present in the tumor microenvironment. Once these molecular results are available, integrate them with the patient’s clinical history to assess their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 12.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 12.0 and transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy? Conduct a comprehensive quantitative analysis of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Subsequently, correlate these molecular findings with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and available transcriptomic profiling data from a bladder biopsy, can we predict her likelihood of responding to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and available transcriptomic profiling data from a bladder biopsy, can we predict her likelihood of responding to atezolizumab therapy? Perform a detailed quantitative evaluation of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Then, integrate these molecular findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"For a white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that Atezolizumab therapy will be effective?","For a white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood that Atezolizumab therapy will be effective? Conduct a thorough quantitative analysis of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages present in the tumor microenvironment. Then, review these molecular findings alongside the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 21.0, whose ureter biopsy provided transcriptomic profiling of the tumor immune microenvironment, is there evidence to suggest that Atezolizumab therapy would be effective?","In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 21.0, whose ureter biopsy provided transcriptomic profiling of the tumor immune microenvironment, is there evidence to suggest that Atezolizumab therapy would be effective? Perform a comprehensive quantitative assessment of gene expression markers specific to exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Next, integrate these molecular results with the patient's clinical history to determine their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"A Caucasian male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment via bladder biopsy, revealing a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment via bladder biopsy, revealing a tumor mutational burden of 14.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Conduct a detailed quantitative analysis of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages present in the tumor microenvironment. Then, correlate these molecular findings with the patient’s clinical history to assess their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"Our patient, a white male with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 9.0. Based on these findings, is he likely to benefit from Atezolizumab therapy?","Our patient, a white male with bladder urothelial carcinoma, has a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 9.0. Based on these findings, is he likely to benefit from Atezolizumab therapy? Perform a comprehensive quantitative analysis of gene expression markers for exhausted T cells, cytotoxic T cells, monocytes, and macrophages within the tumor microenvironment. Then, integrate these molecular findings with the patient’s clinical history to evaluate their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor transcriptomic profile from a bladder biopsy shows a tumor mutation burden (TMB) of 27.0. Based on these findings, is a meaningful response to atezolizumab therapy expected?","I have a white male patient diagnosed with bladder urothelial carcinoma. The tumor transcriptomic profile from a bladder biopsy shows a tumor mutation burden (TMB) of 27.0. Based on these findings, is a meaningful response to atezolizumab therapy expected? Conduct a detailed quantitative evaluation of gene expression markers associated with exhausted T cells, cytotoxic T cells, monocytes, and macrophages in the tumor microenvironment. Then, correlate these molecular findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"The patient presents with bladder urothelial carcinoma, and we have transcriptomic data from a lymph node biopsy characterizing the tumor immune microenvironment. However, the tumor mutation burden is not available (nan). Based on this information, can we predict the patient’s potential response to Atezolizumab therapy?","The patient presents with bladder urothelial carcinoma, and we have transcriptomic data from a lymph node biopsy characterizing the tumor immune microenvironment. However, the tumor mutation burden is not available (nan). Based on this information, can we predict the patient’s potential response to Atezolizumab therapy? Please perform a comprehensive quantitative analysis of gene expression markers for exhausted and cytotoxic T cells, as well as monocytes and macrophages within the tumor microenvironment. Once these molecular results are available, integrate them with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"In a white female patient with bladder urothelial carcinoma and a TMB of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from her kidney biopsy, is there evidence to suggest she would respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma and a TMB of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from her kidney biopsy, is there evidence to suggest she would respond to Atezolizumab therapy? Conduct a detailed quantitative evaluation of gene expression markers for exhausted and cytotoxic T cells, as well as for monocytes and macrophages within the tumor microenvironment. After obtaining these molecular results, integrate them with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile from his tumor immune microenvironment via a bladder biopsy. Given that the tumor mutational burden is undetermined, what are the factors that might predict his response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile from his tumor immune microenvironment via a bladder biopsy. Given that the tumor mutational burden is undetermined, what are the factors that might predict his response to Atezolizumab therapy? Perform a comprehensive quantitative analysis of gene expression markers for exhausted and cytotoxic T cells, as well as markers for monocytes and macrophages within the tumor microenvironment. Then, integrate these molecular findings with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and available transcriptomic data from a bladder biopsy characterizing the tumor immune microenvironment, can we predict if he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and available transcriptomic data from a bladder biopsy characterizing the tumor immune microenvironment, can we predict if he will respond to Atezolizumab therapy? Perform a detailed quantitative assessment of gene expression markers related to exhausted and cytotoxic T cells, as well as markers specific to monocytes and macrophages in the tumor microenvironment. Then, correlate these molecular findings with the patient's clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 4.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 4.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Conduct a comprehensive quantitative analysis of gene expression levels for markers indicative of exhausted and cytotoxic T cells, in addition to specific monocyte and macrophage markers within the tumor microenvironment. After obtaining these molecular profiles, integrate the data with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 5.0, how should the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy inform the potential response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 5.0, how should the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy inform the potential response to Atezolizumab therapy? Perform a detailed, quantitative assessment of gene expression for markers specific to exhausted and cytotoxic T cells, along with key monocyte and macrophage markers within the tumor microenvironment. Once these molecular profiles are obtained, correlate the findings with the patient's clinical history to assess their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0 and available transcriptomic data from the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 15.0 and available transcriptomic data from the tumor immune microenvironment, what is the likelihood of a favorable response to atezolizumab therapy? Quantitatively evaluate the expression of genes associated with exhausted and cytotoxic T cells, as well as key markers for monocytes and macrophages within the tumor microenvironment. After obtaining these molecular profiles, integrate the data with the patient’s clinical history to determine their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,I have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile from a bladder biopsy shows a tumor mutation burden of 13. Could you advise on the likelihood of a positive response to Atezolizumab therapy in this context?,"I have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic profile from a bladder biopsy shows a tumor mutation burden of 13. Could you advise on the likelihood of a positive response to Atezolizumab therapy in this context? Assess the levels of gene expression quantitatively for markers of exhausted T cells, cytotoxic T cells, and key indicators of monocytes and macrophages in the tumor microenvironment. Then, integrate these molecular findings with the patient's clinical history to evaluate their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"In a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, do these findings suggest a likelihood of response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, do these findings suggest a likelihood of response to Atezolizumab therapy? Quantitatively evaluate gene expression levels for markers associated with exhausted T cells, cytotoxic T cells, and key monocyte/macrophage indicators within the tumor microenvironment. Then, correlate these molecular data with the patient’s clinical history to assess their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"I am evaluating a Black/African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17.0 and a transcriptomic profile detailing the tumor immune microenvironment from a bladder biopsy. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I am evaluating a Black/African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17.0 and a transcriptomic profile detailing the tumor immune microenvironment from a bladder biopsy. Based on these findings, can we expect a favorable response to atezolizumab therapy? Measure the gene expression levels of biomarkers for exhausted T cells, cytotoxic T cells, and major monocyte/macrophage populations within the tumor microenvironment. Next, integrate these molecular findings with the patient’s clinical history to evaluate their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"I have a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0. Based on the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, how likely is he to respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0. Based on the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, how likely is he to respond to atezolizumab therapy? Evaluate the expression levels of biomarkers associated with exhausted T cells, cytotoxic T cells, and primary monocyte/macrophage populations in the tumor microenvironment. Then, integrate these molecular data with the patient's clinical history to assess their response to current treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"In a Caucasian patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic immunoprofile from a bladder biopsy, and the tumor mutational burden (TMB) is 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic immunoprofile from a bladder biopsy, and the tumor mutational burden (TMB) is 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Determine and quantify the biomarkers that indicate exhausted T cells, cytotoxic T cells, and the primary monocyte/macrophage populations within the tumor microenvironment. Then, correlate these molecular findings with the patient’s clinical history to evaluate how well they are responding to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"For a Caucasian male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a lung biopsy and has a tumor mutation burden of 20, what can we infer about his potential response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a lung biopsy and has a tumor mutation burden of 20, what can we infer about his potential response to atezolizumab therapy? Assess the levels of biomarkers that signal exhausted T cells, active cytotoxic T cells, and the main monocyte/macrophage subsets in the tumor microenvironment. Then, integrate these molecular data with the patient’s clinical history to determine how effectively they are responding to the ongoing treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 3.0, how likely is it that the patient will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 3.0, how likely is it that the patient will respond to atezolizumab therapy? Evaluate the expression levels of biomarkers associated with exhausted T cells, activated cytotoxic T cells, and the primary monocyte/macrophage populations within the tumor microenvironment. Then, correlate these molecular findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"In a Black or African American male patient with bladder urothelial carcinoma, for whom we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and an indeterminate TMB result, how might we predict his response to Atezolizumab therapy?","In a Black or African American male patient with bladder urothelial carcinoma, for whom we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and an indeterminate TMB result, how might we predict his response to Atezolizumab therapy? Assess the levels of biomarkers that indicate the presence of exhausted T cells, activated cytotoxic T cells, and key monocyte/macrophage populations in the tumor microenvironment. Then, compare these molecular results with the patient's clinical history to determine how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, with available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unavailable tumor mutational burden (TMB), is there an expected therapeutic benefit from Atezolizumab?","In a Caucasian male patient with bladder urothelial carcinoma, with available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unavailable tumor mutational burden (TMB), is there an expected therapeutic benefit from Atezolizumab? Measure the biomarkers associated with exhausted T cells, activated cytotoxic T cells, and key monocyte/macrophage populations within the tumor microenvironment. Then, compare these laboratory findings with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a nanobiopsy revealed a TMB of 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a nanobiopsy revealed a TMB of 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Assess biomarkers reflective of exhausted T cells, activated cytotoxic T cells, and key monocyte/macrophage populations in the tumor microenvironment. Then, correlate these laboratory results with the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"My Caucasian male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden (TMB) of 6.0. Based on these findings, would he be likely to respond to atezolizumab therapy?","My Caucasian male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden (TMB) of 6.0. Based on these findings, would he be likely to respond to atezolizumab therapy? Evaluate biomarkers that indicate the presence of exhausted T cells, activated cytotoxic T cells, and key monocyte/macrophage populations within the tumor microenvironment. Then, integrate these laboratory findings with the patient's clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 17.0. Based on these findings, what is the predicted response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 17.0. Based on these findings, what is the predicted response to atezolizumab therapy? Assess biomarkers that indicate the presence of exhausted T cells, activated cytotoxic T cells, and specific monocyte/macrophage populations within the tumor microenvironment. Next, combine these laboratory results with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor immune microenvironment profile obtained via kidney biopsy and a tumor mutational burden of 6.0. Based on these findings, do you anticipate that he would respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor immune microenvironment profile obtained via kidney biopsy and a tumor mutational burden of 6.0. Based on these findings, do you anticipate that he would respond to atezolizumab therapy? Evaluate biomarkers that reflect the presence of exhausted T cells, activated cytotoxic T cells, and specific monocyte/macrophage subsets in the tumor microenvironment. Then, integrate these laboratory findings with the patient's clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment is available, how likely is it that he will respond to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 1.0, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment is available, how likely is it that he will respond to Atezolizumab therapy? Assess the biomarkers that indicate the presence of exhausted T cells, activated cytotoxic T cells, and distinct monocyte/macrophage populations within the tumor microenvironment. Then, combine these laboratory findings with the patient's clinical history to determine how effectively they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden (TMB) is reported as nan. Given these data, is it likely that the patient will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden (TMB) is reported as nan. Given these data, is it likely that the patient will respond to atezolizumab therapy? Evaluate the biomarkers that signal the presence of exhausted T cells, activated cytotoxic T cells, and various monocyte/macrophage subtypes within the tumor microenvironment. Then, integrate these laboratory findings with the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"For a white female patient with bladder urothelial carcinoma, given that her tumor immune microenvironment transcriptomic profile (from a kidney biopsy) and a tumor mutation burden of 7.0 are available, can we anticipate a favorable response to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, given that her tumor immune microenvironment transcriptomic profile (from a kidney biopsy) and a tumor mutation burden of 7.0 are available, can we anticipate a favorable response to atezolizumab therapy? Review biomarkers that indicate the presence of exhausted T cells, activated cytotoxic T cells, and different monocyte/macrophage populations within the tumor microenvironment. Then, correlate these laboratory findings with the patient's clinical history to assess their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"My patient, a white female diagnosed with bladder urothelial carcinoma, has a tumor transcriptomic profile from a bladder biopsy and a tumor mutational burden of 21.0. Based on this data, is a favorable response to Atezolizumab therapy likely?","My patient, a white female diagnosed with bladder urothelial carcinoma, has a tumor transcriptomic profile from a bladder biopsy and a tumor mutational burden of 21.0. Based on this data, is a favorable response to Atezolizumab therapy likely? Examine the biomarkers indicating exhausted T cells, activated cytotoxic T cells, and various monocyte/macrophage populations within the tumor microenvironment. Then, integrate these laboratory results with the patient’s clinical history to evaluate their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy reveals a TMB of 7.0 mutations per megabase. Based on these findings, how likely is he to benefit from atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy reveals a TMB of 7.0 mutations per megabase. Based on these findings, how likely is he to benefit from atezolizumab therapy? Review the biomarker profile for exhausted T cells, activated cytotoxic T cells, and the distinct monocyte/macrophage subsets present in the tumor microenvironment. Then, correlate these laboratory findings with the patient’s clinical history to determine their current response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"Our patient is a white male with bladder urothelial carcinoma. His tumor immune microenvironment, as assessed by transcriptomic profiling from a lung biopsy, shows a tumor mutation burden of 6.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","Our patient is a white male with bladder urothelial carcinoma. His tumor immune microenvironment, as assessed by transcriptomic profiling from a lung biopsy, shows a tumor mutation burden of 6.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Examine the patient's biomarker data for exhausted T cells, activated cytotoxic T cells, and the specific monocyte/macrophage subsets in the tumor microenvironment. Then, integrate these laboratory results with the patient’s clinical history to assess their response to the current therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, is there evidence to support that Atezolizumab therapy would be clinically beneficial?","In a Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, is there evidence to support that Atezolizumab therapy would be clinically beneficial? Review the patient’s biomarker profile focusing on exhausted T cells, activated cytotoxic T cells, and the specific monocyte/macrophage subsets present in the tumor microenvironment. Then, combine these laboratory results with the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. Given that the tumor mutation burden value is not available, is there evidence to suggest that he might respond favorably to atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment. Given that the tumor mutation burden value is not available, is there evidence to suggest that he might respond favorably to atezolizumab therapy? Examine the patient's biomarker profile by specifically assessing exhausted T cells, activated cytotoxic T cells, and the defined monocyte/macrophage subsets within the tumor microenvironment. Then, integrate these laboratory findings with the patient's clinical history to determine their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 3.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 3.0, what is the likelihood of a favorable response to atezolizumab therapy? Review the patient's biomarker profile, with a focus on exhausted T cells, activated cytotoxic T cells, and specific monocyte/macrophage subsets within the tumor microenvironment. Then, combine these laboratory results with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA), we have transcriptomic data from his tumor immune microenvironment and a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is it that he would respond to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA), we have transcriptomic data from his tumor immune microenvironment and a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is it that he would respond to Atezolizumab therapy? Please assess the patient’s immune profile by examining markers for exhausted T cells, activated cytotoxic T cells, and specific monocyte/macrophage subsets within the tumor environment. Then, integrate these laboratory findings with the patient’s clinical history to determine how well they are responding to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,For a white male patient with bladder urothelial carcinoma who has undergone a bladder biopsy yielding a transcriptomic profile of the tumor immune microenvironment—and with tumor mutational burden data not available—how should we interpret his likelihood of responding to atezolizumab therapy?,"For a white male patient with bladder urothelial carcinoma who has undergone a bladder biopsy yielding a transcriptomic profile of the tumor immune microenvironment—and with tumor mutational burden data not available—how should we interpret his likelihood of responding to atezolizumab therapy? Evaluate the patient’s immune status by analyzing markers for exhausted T cells, activated cytotoxic T cells, and particular monocyte/macrophage subsets within the tumor microenvironment. Then, correlate these laboratory findings with the patient’s clinical history to determine their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For a white female patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a ureter biopsy indicates specific characteristics of the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a ureter biopsy indicates specific characteristics of the tumor immune microenvironment, and the tumor mutational burden is 12.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Assess the patient's immune profile by measuring markers for exhausted T cells, activated cytotoxic T cells, and specific monocyte/macrophage subsets within the tumor microenvironment. Then, integrate these laboratory findings with the patient's clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment was obtained via a ureter biopsy. Notably, his tumor mutation burden (TMB) has not been determined. Based on this information, can we infer whether he is likely to respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profile of the tumor immune microenvironment was obtained via a ureter biopsy. Notably, his tumor mutation burden (TMB) has not been determined. Based on this information, can we infer whether he is likely to respond to Atezolizumab therapy? Evaluate the immune profile by quantifying markers of T cell exhaustion, activated cytotoxic T cells, and particular monocyte/macrophage subsets within the tumor microenvironment. Then, correlate these laboratory results with the patient’s clinical history to determine how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), given a tumor mutation burden of 5.0 and the available transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is it likely that she will respond to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), given a tumor mutation burden of 5.0 and the available transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, is it likely that she will respond to atezolizumab therapy? Assess the immune status of the tumor microenvironment by measuring the levels of T cell exhaustion markers, activated cytotoxic T cells, and specific monocyte/macrophage subsets. Then, review these laboratory findings in the context of the patient’s medical history to gauge their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a therapeutic response to atezolizumab?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a therapeutic response to atezolizumab? Evaluate the tumor microenvironment by quantitatively measuring T cell exhaustion markers, activated cytotoxic T cells, and specific monocyte/macrophage subsets. Then, interpret these results in light of the patient’s medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"I have a white male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 8.0. Given these findings, how likely is he to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 8.0. Given these findings, how likely is he to respond to atezolizumab therapy? Assess the tumor microenvironment by quantitatively evaluating markers of T cell exhaustion, activated cytotoxic T cells, and key monocyte/macrophage populations. Then, integrate these findings with the patient’s medical history to determine how well they are responding to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is not available. Based on the current data, do you think he is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is not available. Based on the current data, do you think he is likely to respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers that indicate T cell exhaustion, activated cytotoxic T cells, and specific monocyte/macrophage subsets. Next, combine these findings with the patient’s medical history to assess their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"In a Black/African American male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 1.0 and has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","In a Black/African American male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 1.0 and has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Assess the tumor microenvironment by measuring markers associated with T cell exhaustion, active cytotoxic T cells, and specific monocyte/macrophage subsets. Then, integrate these findings with the patient’s medical history to evaluate their current response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what can we infer about his likelihood of responding to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what can we infer about his likelihood of responding to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers for T cell exhaustion, activated cytotoxic T cells, and specific monocyte/macrophage subsets. Then, review these results in the context of the patient’s clinical history to assess their current response to therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"A white male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a tumor mutational burden of 8.0. Based on these findings, do you anticipate that the patient would respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a tumor mutational burden of 8.0. Based on these findings, do you anticipate that the patient would respond to atezolizumab therapy? Assess the tumor microenvironment by measuring biomarkers for T cell exhaustion, activated cytotoxic T lymphocytes, and targeted monocyte/macrophage subsets. Then, correlate these findings with the patient’s clinical history to evaluate their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and who has a tumor mutational burden (TMB) of 7.0, what is the likelihood that she will respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and who has a tumor mutational burden (TMB) of 7.0, what is the likelihood that she will respond to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying biomarkers for T cell exhaustion, activated cytotoxic T lymphocytes, and specific monocyte/macrophage populations. Then, integrate these results with the patient’s clinical history to assess their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a white male patient with bladder urothelial carcinoma. We have a transcriptomic profile of the tumor immune microenvironment from a prior biopsy, but the tumor mutational burden data is not available. Based on these findings, can we predict whether the patient will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We have a transcriptomic profile of the tumor immune microenvironment from a prior biopsy, but the tumor mutational burden data is not available. Based on these findings, can we predict whether the patient will respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, the presence of activated cytotoxic T lymphocytes, and key monocyte/macrophage populations. After obtaining these results, review the patient’s clinical history to determine their current treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a bladder biopsy shows a TMB of 5.0. Based on this molecular and immune microenvironment data, is he likely to respond favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from a bladder biopsy shows a TMB of 5.0. Based on this molecular and immune microenvironment data, is he likely to respond favorably to atezolizumab therapy? Evaluate the tumor microenvironment by determining biomarkers that signal T cell exhaustion, the presence of activated cytotoxic T lymphocytes, and major monocyte/macrophage populations. After collecting these biomarker data, review the patient’s clinical history to assess their current response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"For a white male patient with urothelial carcinoma of the bladder, who has a tumor mutational burden of 8.0 and a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with urothelial carcinoma of the bladder, who has a tumor mutational burden of 8.0 and a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, the activity of cytotoxic T lymphocytes, and the presence of key monocyte/macrophage populations. Once you have these data, review the patient’s clinical history to determine how they are currently responding to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 14.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, is it likely that she will respond favorably to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 14.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, is it likely that she will respond favorably to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying biomarkers associated with T cell exhaustion, the activity of cytotoxic T lymphocytes, and specific monocyte/macrophage populations. After obtaining these measurements, review the patient’s clinical history to assess their response to current treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a TMB of 13.0. Based on these findings, is he likely to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a TMB of 13.0. Based on these findings, is he likely to respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, cytotoxic T lymphocyte activity, and the presence of specific monocyte/macrophage subsets. Then, review the patient’s clinical records to determine how well they have responded to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For an Asian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and available transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the likelihood that he would respond to atezolizumab therapy?","For an Asian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and available transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the likelihood that he would respond to atezolizumab therapy? Evaluate the tumor microenvironment by quantifying biomarkers associated with T cell exhaustion, the activity of cytotoxic T lymphocytes, and specific monocyte/macrophage subsets. Following this analysis, review the patient's clinical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutation burden of 7.0. Based on this information, how likely is it that the patient will respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutation burden of 7.0. Based on this information, how likely is it that the patient will respond to Atezolizumab therapy? Assess the tumor microenvironment by measuring biomarkers that reflect T cell exhaustion, cytotoxic T lymphocyte activity, and the presence of specific monocyte/macrophage subsets. Then, review the patient’s clinical records to determine how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 6.0 are available. How might these findings inform his likely response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 6.0 are available. How might these findings inform his likely response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying biomarkers that indicate T cell exhaustion, cytotoxic T lymphocyte activity, and the distribution of specific monocyte/macrophage subpopulations. Then, review the patient's clinical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 6.0, with a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 6.0, with a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that he will respond to atezolizumab therapy? Assess the tumor microenvironment by quantifying biomarkers for T cell exhaustion, measuring cytotoxic T lymphocyte activity, and characterizing the distribution of specific monocyte/macrophage subpopulations. Then, review the patient’s clinical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 5.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that Atezolizumab therapy would be effective?","In a Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 5.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there evidence to suggest that Atezolizumab therapy would be effective? Evaluate the tumor microenvironment by quantifying biomarkers linked to T cell exhaustion, measuring cytotoxic T lymphocyte activity, and characterizing the pattern of specific monocyte/macrophage subpopulations. Then, review the patient's clinical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 49.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, how likely is he to respond to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 49.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, how likely is he to respond to atezolizumab therapy? Assess the tumor microenvironment by quantifying biomarkers associated with T cell exhaustion, evaluating the activity of cytotoxic T lymphocytes, and profiling the distribution of specific monocyte/macrophage populations. Then, review the patient's clinical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 12.0, based on a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 12.0, based on a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring biomarkers related to T cell exhaustion, assessing cytotoxic T cell activity, and characterizing the distribution of specific monocyte/macrophage subsets. Next, review the patient's clinical records to determine how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment from a bladder biopsy has been obtained, and his tumor mutational burden is reported as ""nan."" Based on these findings, can we predict if he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. The transcriptomic profile of his tumor immune microenvironment from a bladder biopsy has been obtained, and his tumor mutational burden is reported as ""nan."" Based on these findings, can we predict if he will respond to atezolizumab therapy? Assess the tumor microenvironment by quantifying biomarkers indicative of T cell exhaustion, evaluating cytotoxic T cell function, and identifying the spread of specific monocyte/macrophage subtypes. Then, review the patient's clinical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"My white male patient with bladder urothelial carcinoma has undergone a bladder biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. His tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","My white male patient with bladder urothelial carcinoma has undergone a bladder biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. His tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring biomarkers that indicate T cell exhaustion, assessing the function of cytotoxic T cells, and mapping the distribution of specific monocyte/macrophage subtypes. Then, review the patient's medical records to determine how they are responding to their current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For a Black/African American male patient with bladder urothelial carcinoma (BLCA), who has undergone a kidney biopsy yielding a transcriptomic profile of the tumor immune microenvironment and exhibits a tumor mutational burden (TMB) of 11.0, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","For a Black/African American male patient with bladder urothelial carcinoma (BLCA), who has undergone a kidney biopsy yielding a transcriptomic profile of the tumor immune microenvironment and exhibits a tumor mutational burden (TMB) of 11.0, what is the predicted likelihood of a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying biomarkers that indicate T cell exhaustion, evaluating the functional capacity of cytotoxic T cells, and characterizing the spatial distribution of specific monocyte/macrophage subsets. Then, review the patient's medical records to evaluate their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a bladder biopsy, and his tumor mutational burden (TMB) is not available. Based on these molecular findings, what is the likelihood that he will respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a bladder biopsy, and his tumor mutational burden (TMB) is not available. Based on these molecular findings, what is the likelihood that he will respond to atezolizumab therapy? Evaluate the tumor microenvironment by measuring biomarkers that reflect T cell exhaustion, assessing the activity of cytotoxic T cells, and analyzing the spatial arrangement of particular monocyte/macrophage populations. Additionally, review the patient's medical records to determine how they are responding to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a ureter biopsy, but his tumor mutational burden (TMB) is reported as not available. Based on these findings, how should we assess his potential response to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor immune microenvironment from a ureter biopsy, but his tumor mutational burden (TMB) is reported as not available. Based on these findings, how should we assess his potential response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying biomarkers indicative of T cell exhaustion, evaluating the activity of cytotoxic T cells, and examining the spatial distribution of specific monocyte/macrophage subsets. Also, review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 17.0, based on the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 17.0, based on the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please evaluate the tumor environment by quantifying biomarkers associated with T cell exhaustion, assessing the function of cytotoxic T cells, and analyzing the spatial distribution of targeted monocyte/macrophage subtypes. Additionally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"In a Caucasian patient diagnosed with bladder urothelial carcinoma, given a tumor mutational burden of 22.0 and transcriptomic profiling data from the tumor immune microenvironment obtained via bladder biopsy, would treatment with Atezolizumab be expected to yield a favorable clinical response?","In a Caucasian patient diagnosed with bladder urothelial carcinoma, given a tumor mutational burden of 22.0 and transcriptomic profiling data from the tumor immune microenvironment obtained via bladder biopsy, would treatment with Atezolizumab be expected to yield a favorable clinical response? Please assess the tumor microenvironment by measuring biomarkers of T cell exhaustion and evaluating cytotoxic T cell functionality. Also, analyze the spatial distribution of specific monocyte/macrophage subsets. Additionally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"My white male patient has bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these data, what can be deduced about the likelihood of response to Atezolizumab therapy?","My white male patient has bladder urothelial carcinoma. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these data, what can be deduced about the likelihood of response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers of T cell exhaustion and assessing the activity of cytotoxic T cells. Additionally, analyze the spatial distribution of specific monocyte/macrophage subsets. Finally, review the patient’s medical records to determine their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"For a patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the anticipated response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the anticipated response to atezolizumab therapy? Assess the tumor microenvironment by measuring markers of T cell exhaustion and evaluating cytotoxic T cell activity. Additionally, determine the spatial distribution of specific monocyte/macrophage subsets. Finally, review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"For a white male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutation burden of 5.0 have been obtained. Based on these data, can we predict a likely response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutation burden of 5.0 have been obtained. Based on these data, can we predict a likely response to atezolizumab therapy? Please evaluate the tumor microenvironment by quantifying markers of T cell exhaustion along with assessments of cytotoxic T cell activity. In addition, map out the spatial distribution of targeted monocyte/macrophage subsets, and review the patient’s medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"My Caucasian male patient has been diagnosed with bladder urothelial carcinoma. His tumor microenvironment has been profiled via transcriptomics from a bladder biopsy, and his tumor mutational burden is 4.0. Based on this information, is it likely that he will respond to atezolizumab therapy?","My Caucasian male patient has been diagnosed with bladder urothelial carcinoma. His tumor microenvironment has been profiled via transcriptomics from a bladder biopsy, and his tumor mutational burden is 4.0. Based on this information, is it likely that he will respond to atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers associated with T cell exhaustion and assessing cytotoxic T cell activity. Additionally, delineate the spatial distribution of specific monocyte/macrophage subsets. Please also review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0. We have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0. We have a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy? Please assess the tumor microenvironment by measuring markers indicative of T cell exhaustion and evaluating the activity of cytotoxic T cells. Also, map out the spatial distribution of specific monocyte/macrophage subsets. Lastly, review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy has been performed. Could these data help predict his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy has been performed. Could these data help predict his likelihood of responding to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers of T cell exhaustion and assessing the functional activity of cytotoxic T cells. Additionally, determine the spatial distribution of defined monocyte/macrophage subsets. Finally, review the patient’s medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has an indeterminate tumor mutational burden, is atezolizumab likely to be effective as a treatment option?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has an indeterminate tumor mutational burden, is atezolizumab likely to be effective as a treatment option? Please assess the tumor microenvironment by quantifying the expression of T cell exhaustion markers and evaluating the functional activity of cytotoxic T cells. Also, map the spatial distribution of the specific monocyte/macrophage subsets present. Finally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"For a white female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy is available and the tumor mutational burden is indeterminate (reported as ""nan""), what is the likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy is available and the tumor mutational burden is indeterminate (reported as ""nan""), what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring the levels of T cell exhaustion markers and assessing the functional activity of cytotoxic T cells. Additionally, chart the spatial distribution of relevant monocyte/macrophage subsets. Finally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. His tumor mutation burden is 10.0 mutations per megabase. Based on these data, can we predict a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. His tumor mutation burden is 10.0 mutations per megabase. Based on these data, can we predict a favorable response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying T cell exhaustion markers and evaluating the functional activity of cytotoxic T cells. Also, map the spatial distribution of key monocyte/macrophage subsets. Lastly, review the patient's medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 6.0, what is the expected response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 6.0, what is the expected response to Atezolizumab therapy? Evaluate the tumor microenvironment by measuring markers of T cell exhaustion and determining the functional activity of cytotoxic T cells. Additionally, document the spatial distribution of significant monocyte/macrophage subsets. Finally, review the patient’s medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"I have a Caucasian female patient with bladder urothelial carcinoma, and we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. Considering that her reported tumor mutational burden value is not available (NAN), how should we interpret the potential response to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma, and we have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. Considering that her reported tumor mutational burden value is not available (NAN), how should we interpret the potential response to Atezolizumab therapy? Assess the tumor microenvironment by quantifying markers of T cell exhaustion and evaluating the functional activity of cytotoxic T cells. Also, record the spatial patterns of key monocyte and macrophage subsets. Finally, review the patient's medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"In a white female patient with bladder urothelial carcinoma, who exhibits a tumor mutational burden of 15.0 and has available transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, who exhibits a tumor mutational burden of 15.0 and has available transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment by quantifying markers related to T cell exhaustion and assessing the functional activity of cytotoxic T cells. Additionally, document the spatial distribution of important monocyte and macrophage subsets. Finally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA), and his lymph node biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood of his responding to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA), and his lymph node biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood of his responding to Atezolizumab therapy? Assess the tumor microenvironment by quantifying markers indicative of T cell exhaustion and evaluating the functional activity of cytotoxic T cells. Additionally, document the spatial distribution of key monocyte and macrophage subsets. Finally, review the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on these findings, how likely is it that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on these findings, how likely is it that he will respond to atezolizumab therapy? Evaluate the tumor microenvironment by measuring markers of T cell exhaustion and assessing the functional activity of cytotoxic T cells. At the same time, record the spatial distribution of key monocyte and macrophage subsets. Finally, review the patient's medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden (TMB) of 19.0, is there evidence to support a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden (TMB) of 19.0, is there evidence to support a favorable response to atezolizumab therapy? Assess the tumor microenvironment as follows: first, measure markers associated with T cell exhaustion and evaluate the functional activity of cytotoxic T cells; second, document the spatial distribution of critical monocyte and macrophage subsets; and finally, review the patient's medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomics and who has a tumor mutation burden of 12, what is the likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled via transcriptomics and who has a tumor mutation burden of 12, what is the likelihood of response to Atezolizumab therapy? Review the tumor microenvironment by following these steps: 

1. Evaluate markers indicative of T cell exhaustion and assess the functional activity of cytotoxic T cells. 
2. Map the spatial distribution of key monocyte and macrophage subsets.
3. Examine the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment via kidney biopsy. Given that the tumor mutational burden (TMB) is not available, can we use the existing data to predict the likelihood of a positive response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) for whom we obtained a transcriptomic profile of the tumor immune microenvironment via kidney biopsy. Given that the tumor mutational burden (TMB) is not available, can we use the existing data to predict the likelihood of a positive response to Atezolizumab therapy? Assess the tumor microenvironment using the following steps:

1. Evaluate markers of T cell exhaustion and determine the functional activity of cytotoxic T lymphocytes.
2. Map the spatial distribution of key monocyte and macrophage subsets.
3. Review the patient's medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA). His biopsy-based transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 3.0 mutations per megabase. Based on these findings, is Atezolizumab therapy likely to be effective for him?","I have a white male patient with bladder urothelial carcinoma (BLCA). His biopsy-based transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 3.0 mutations per megabase. Based on these findings, is Atezolizumab therapy likely to be effective for him? Begin by evaluating T cell exhaustion markers and quantifying the functional activity of cytotoxic T lymphocytes. Next, delineate the spatial distribution of key monocyte and macrophage subsets. Finally, review the patient's medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"We have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 18.0, and we obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 18.0, and we obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? First, assess T cell exhaustion markers and reliably measure the functional activity of cytotoxic T lymphocytes. Then, map the spatial arrangement of key monocyte and macrophage subsets. Finally, examine the patient’s medical history to evaluate their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 15.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 15.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Begin by evaluating markers of T cell exhaustion and accurately assess the functional activity of cytotoxic T lymphocytes. Next, delineate the spatial distribution of key monocyte and macrophage subsets. Finally, review the patient’s medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a lymph node biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. Given that his tumor mutation burden is not available, can we predict his likelihood of responding to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a lymph node biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. Given that his tumor mutation burden is not available, can we predict his likelihood of responding to Atezolizumab therapy? First, assess markers indicative of T cell exhaustion and carefully evaluate the functional activity of the cytotoxic T lymphocytes. Then, map the spatial distribution of the key subsets of monocytes and macrophages. Finally, review the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"In a white female patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy is available, but the tumor mutational burden is reported as unavailable (nan). Given these findings, what is the likelihood that she will respond to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy is available, but the tumor mutational burden is reported as unavailable (nan). Given these findings, what is the likelihood that she will respond to atezolizumab therapy? Begin by evaluating markers associated with T cell exhaustion and assessing the function of cytotoxic T lymphocytes. Next, chart the spatial distribution of key monocyte and macrophage subsets. Finally, review the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor mutational burden is 6.0, and we obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. His tumor mutational burden is 6.0, and we obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? First, evaluate markers that indicate T cell exhaustion and measure the functional capacity of cytotoxic T lymphocytes. Next, use spatial analysis techniques to map the distribution of critical monocyte and macrophage subsets. Finally, review the patient’s clinical history to determine how they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For a Caucasian female patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden reported as NaN, would Atezolizumab be an appropriate therapy option?","For a Caucasian female patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden reported as NaN, would Atezolizumab be an appropriate therapy option? First, assess indicators of T cell exhaustion and determine the functional capacity of cytotoxic T lymphocytes. Next, employ spatial analysis methods to delineate the distribution of key monocyte and macrophage subsets. Finally, review the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"For a Black or African American patient with bladder urothelial carcinoma who has had transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy and with a reported tumor mutational burden of ""nan,"" is there evidence to suggest a favorable response to atezolizumab therapy?","For a Black or African American patient with bladder urothelial carcinoma who has had transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy and with a reported tumor mutational burden of ""nan,"" is there evidence to suggest a favorable response to atezolizumab therapy? First, evaluate markers of T cell exhaustion and measure the effectiveness of cytotoxic T lymphocytes. Then, utilize spatial analysis techniques to map the distribution of key monocyte and macrophage subsets. Finally, review the patient's clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden is not available. Based on these data, how likely is she to respond to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, but her tumor mutation burden is not available. Based on these data, how likely is she to respond to atezolizumab therapy? Begin by assessing markers indicative of T cell exhaustion and evaluating the functional capacity of cytotoxic T lymphocytes. Next, apply spatial analysis methods to delineate the distribution of essential monocyte and macrophage subsets. Finally, review the patient’s clinical history to assess their response to the current treatment protocol.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and transcriptomic data from a ureteral biopsy of the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 4.0 and transcriptomic data from a ureteral biopsy of the tumor immune microenvironment, what is the likelihood that he will respond to Atezolizumab therapy? First, evaluate markers associated with T cell exhaustion and determine the functional status of cytotoxic T lymphocytes. Then, use spatial analysis techniques to map out the distribution of key monocyte and macrophage subsets. Finally, review the patient's clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor mutational burden is 14.0, and we have transcriptomic data from his tumor immune microenvironment obtained via bladder biopsy. Based on these findings, what is the likelihood of his responding to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose tumor mutational burden is 14.0, and we have transcriptomic data from his tumor immune microenvironment obtained via bladder biopsy. Based on these findings, what is the likelihood of his responding to Atezolizumab therapy? Begin by assessing markers of T cell exhaustion and the functional status of cytotoxic T lymphocytes. Then, apply spatial analysis methods to delineate the distribution of key monocyte and macrophage populations. Finally, review the patient's clinical history to evaluate their response to the current treatment protocol.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile was derived via transcriptomic analysis from a lung biopsy, and who has a tumor mutational burden of 7.0, do you anticipate a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile was derived via transcriptomic analysis from a lung biopsy, and who has a tumor mutational burden of 7.0, do you anticipate a favorable response to Atezolizumab therapy? Start by evaluating markers indicative of T cell exhaustion and determining the functional status of cytotoxic T lymphocytes. Next, employ spatial analysis techniques to map the distribution of significant monocyte and macrophage populations. Finally, carefully review the patient’s clinical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a lung biopsy and has a tumor mutation burden of 3.0, what is the likelihood of a response to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a lung biopsy and has a tumor mutation burden of 3.0, what is the likelihood of a response to atezolizumab therapy? Begin by assessing biomarkers of T cell exhaustion and determining the functional status of cytotoxic T lymphocytes. Then, use spatial analysis techniques to chart the location and distribution of key monocyte and macrophage populations. Finally, review the patient’s clinical history to evaluate their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 11.0. Based on these molecular findings, what is the likelihood he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 11.0. Based on these molecular findings, what is the likelihood he will respond to atezolizumab therapy? First, evaluate biomarkers that indicate T cell exhaustion and assess the functional status of cytotoxic T lymphocytes. Next, apply spatial analysis methods to map where key monocyte and macrophage populations are located. Finally, review the patient’s clinical history to determine how they are responding to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"Our patient is a Caucasian female with bladder urothelial carcinoma. Given that her tumor microenvironment transcriptomic profile obtained from a bladder biopsy indicates a tumor mutational burden of 4.0, can we expect a favorable response to Atezolizumab therapy?","Our patient is a Caucasian female with bladder urothelial carcinoma. Given that her tumor microenvironment transcriptomic profile obtained from a bladder biopsy indicates a tumor mutational burden of 4.0, can we expect a favorable response to Atezolizumab therapy? Begin by assessing biomarkers that signal T cell exhaustion and evaluate the functionality of cytotoxic T lymphocytes. Then, use spatial analysis techniques to determine the distribution of key monocyte and macrophage populations. Finally, review the patient’s clinical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"In a white female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, but the tumor mutation burden data is unavailable. Based on this information, can we predict her likely response to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, but the tumor mutation burden data is unavailable. Based on this information, can we predict her likely response to atezolizumab therapy? First, evaluate the biomarkers associated with T cell exhaustion and assess the function of cytotoxic T lymphocytes. Next, apply spatial analysis methods to map key monocyte and macrophage populations. Lastly, review the patient’s clinical history to assess how well they are responding to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"A white male patient with bladder urothelial carcinoma has undergone a bladder biopsy, yielding a transcriptomic profile of the tumor immune microenvironment. Given that the reported tumor mutational burden (TMB) data are not available (NaN), can we anticipate a response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone a bladder biopsy, yielding a transcriptomic profile of the tumor immune microenvironment. Given that the reported tumor mutational burden (TMB) data are not available (NaN), can we anticipate a response to Atezolizumab therapy? Step 1: Assess biomarkers indicative of T cell exhaustion and evaluate the functionality of cytotoxic T lymphocytes. 

Step 2: Utilize spatial analysis techniques to map and quantify key populations of monocytes and macrophages.

Step 3: Review the patient’s clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"I am evaluating a white male patient with bladder urothelial carcinoma. His tumor transcriptomic profile, obtained from a previous biopsy, indicates a tumor mutational burden of 18.0. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy?","I am evaluating a white male patient with bladder urothelial carcinoma. His tumor transcriptomic profile, obtained from a previous biopsy, indicates a tumor mutational burden of 18.0. Based on these findings, what is the likelihood that he will respond favorably to atezolizumab therapy? 1. Begin by evaluating biomarkers related to T cell exhaustion and assessing the performance of cytotoxic T lymphocytes. 

2. Next, apply spatial analysis methods to accurately map and quantify key populations of monocytes and macrophages. 

3. Finally, review the patient's clinical history to gauge their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden (TMB) of 19.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden (TMB) of 19.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? 1. First, assess biomarkers indicative of T cell exhaustion and evaluate the activity of cytotoxic T lymphocytes.  
2. Then, use spatial analysis techniques to accurately identify and quantify key populations of monocytes and macrophages.  
3. Finally, review the patient's clinical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"Our patient is a white male with bladder urothelial carcinoma. We have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 35.0. Based on these findings, do you think he is likely to respond favorably to Atezolizumab therapy?","Our patient is a white male with bladder urothelial carcinoma. We have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 35.0. Based on these findings, do you think he is likely to respond favorably to Atezolizumab therapy? 1. Evaluate biomarkers that indicate T cell exhaustion and assess the functional activity of cytotoxic T lymphocytes.  
2. Utilize spatial analysis methods to accurately identify and quantify the critical populations of monocytes and macrophages.  
3. Review the patient’s clinical record to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"My white male patient diagnosed with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a kidney biopsy, and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","My white male patient diagnosed with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile from a kidney biopsy, and a tumor mutational burden of 5.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? 1. Review biomarkers linked to T cell exhaustion and assess the functional status of cytotoxic T lymphocytes.  
2. Apply spatial analysis techniques to accurately identify and quantify key monocyte and macrophage populations.  
3. Examine the patient's clinical record to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, considering the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 5.0, is Atezolizumab therapy likely to be effective?","In a Caucasian male patient with bladder urothelial carcinoma, considering the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 5.0, is Atezolizumab therapy likely to be effective? 1. Evaluate the biomarkers that indicate T cell exhaustion and determine the functional capacity of cytotoxic T lymphocytes.
2. Utilize spatial analysis methods to accurately identify and quantify the major monocyte and macrophage populations.
3. Review the patient’s clinical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 16.0. Given these findings, how likely is it that he will respond favorably to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 16.0. Given these findings, how likely is it that he will respond favorably to atezolizumab therapy? 1. Assess the biomarkers associated with T cell exhaustion and determine the functional activity of cytotoxic T lymphocytes.  
2. Apply spatial analysis techniques to accurately identify and quantify the primary populations of monocytes and macrophages.  
3. Examine the patient’s medical records to evaluate their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"I have a patient with bladder urothelial carcinoma who has a TMB of 8.0. We have also completed transcriptomic profiling of the tumor's immune microenvironment from a bladder biopsy. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who has a TMB of 8.0. We have also completed transcriptomic profiling of the tumor's immune microenvironment from a bladder biopsy. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy? 1. Evaluate biomarker levels indicative of T cell exhaustion and determine the functional activity of cytotoxic T lymphocytes.  
2. Utilize spatial analysis techniques to precisely identify and quantify the key populations of monocytes and macrophages.  
3. Review the patient’s medical records to assess their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood that he will respond to atezolizumab therapy? 1. Assess biomarker levels that indicate T cell exhaustion and evaluate the functional capacity of cytotoxic T lymphocytes.  
2. Apply spatial analysis methods to accurately locate and enumerate the main populations of monocytes and macrophages.  
3. Examine the patient’s medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden is 5.0 mutations/Mb. What are the implications of these findings regarding her potential response to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, and her tumor mutation burden is 5.0 mutations/Mb. What are the implications of these findings regarding her potential response to atezolizumab therapy? 1. Begin by measuring specific biomarkers to evaluate T cell exhaustion and determine the functional status of cytotoxic T lymphocytes.  
2. Use spatial analysis techniques to precisely locate and quantify the primary populations of monocytes and macrophages.  
3. Review the patient’s medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For my Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, is she likely to respond to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 7.0, based on the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, is she likely to respond to Atezolizumab therapy? 1. Measure relevant biomarkers to assess T cell exhaustion and evaluate the functional capacity of cytotoxic T lymphocytes.
2. Employ spatial analysis methods to accurately identify and quantify the main populations of monocytes and macrophages in the tissue.
3. Review the patient's medical records to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has undergone a bladder biopsy, and we have acquired a transcriptomic profile of the tumor immune microenvironment. However, the tumor mutation burden data is not available. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has undergone a bladder biopsy, and we have acquired a transcriptomic profile of the tumor immune microenvironment. However, the tumor mutation burden data is not available. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy? 1. Assess biomarkers indicative of T cell exhaustion and determine the functional status of cytotoxic T lymphocytes.  
2. Apply spatial analysis techniques to reliably detect and quantify the predominant monocyte and macrophage populations within the tissue.  
3. Review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutation burden (TMB) of 9.0, can we anticipate a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutation burden (TMB) of 9.0, can we anticipate a favorable response to Atezolizumab therapy? 1. Evaluate biomarkers for T cell exhaustion to determine how effectively cytotoxic T cells are functioning.  
2. Use spatial analysis methods to accurately identify and measure the main monocyte and macrophage populations in the tissue sample.  
3. Examine the patient's medical records to assess their response to the current therapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"I have a white female patient with bladder urothelial carcinoma (BLCA) who presents with a tumor mutation burden of 20.0. Given the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, is she likely to respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA) who presents with a tumor mutation burden of 20.0. Given the transcriptomic profile of the tumor immune microenvironment from her bladder biopsy, is she likely to respond to Atezolizumab therapy? 1. Assess biomarkers indicative of T cell exhaustion to gauge the functional efficiency of the cytotoxic T cell response.
2. Apply spatial analysis techniques to accurately identify and quantify the primary monocyte and macrophage populations within the tissue sample.
3. Review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"A white female patient with bladder urothelial carcinoma has a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 10.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","A white female patient with bladder urothelial carcinoma has a transcriptomic profile of her tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 10.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? 1. Evaluate biomarkers related to T cell exhaustion to determine how effectively the cytotoxic T cells are functioning.
2. Use spatial analysis methods to accurately identify and measure the principal monocyte and macrophage populations in the tissue sample.
3. Examine the patient’s medical records to assess their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy revealing a tumor mutational burden (TMB) of 35. Based on this profile, is there evidence suggesting that he would likely respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile from a bladder biopsy revealing a tumor mutational burden (TMB) of 35. Based on this profile, is there evidence suggesting that he would likely respond to Atezolizumab therapy? 1. Examine biomarkers of T cell exhaustion to assess the functional performance of cytotoxic T cells.
2. Apply spatial analysis techniques to accurately locate and quantify the main monocyte and macrophage populations within the tissue sample.
3. Review the patient’s medical records to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Her bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden is 6.0. Based on these data, would you anticipate a favorable response to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Her bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden is 6.0. Based on these data, would you anticipate a favorable response to atezolizumab therapy? 1. Assess the biomarkers linked to T cell exhaustion to determine the functional effectiveness of cytotoxic T cells.
2. Employ spatial analysis methods to precisely identify and quantify the primary monocyte and macrophage populations within the tissue sample.
3. Review the patient's medical records to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"I have a white female patient with bladder urothelial carcinoma, and we recently obtained the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. With a tumor mutational burden of 3.0 mutations per megabase, what are the indicators that she might respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma, and we recently obtained the transcriptomic profile of her tumor immune microenvironment from a bladder biopsy. With a tumor mutational burden of 3.0 mutations per megabase, what are the indicators that she might respond to Atezolizumab therapy? 1. Evaluate biomarkers indicative of T cell exhaustion to determine the functionality of cytotoxic T cells.
2. Use spatial analysis techniques to accurately locate and quantify the main monocyte and macrophage populations within the tissue sample.
3. Examine the patient's medical records to assess their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) reveals a TMB of 5.0. Based on these findings, can we expect a favorable response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) reveals a TMB of 5.0. Based on these findings, can we expect a favorable response to atezolizumab therapy? 1. Assess biomarkers of T cell exhaustion to determine the current functional status of the cytotoxic T cells.  
2. Apply spatial analysis methods to accurately identify and quantify the key populations of monocytes and macrophages within the tissue specimen.  
3. Review the patient’s medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile (obtained via nanobiopsy) shows a tumor mutational burden of 5.0, what is the likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile (obtained via nanobiopsy) shows a tumor mutational burden of 5.0, what is the likelihood of a positive response to atezolizumab therapy? 1. Evaluate markers indicative of T cell exhaustion to determine the functional status of cytotoxic T cells.  
2. Utilize spatial analysis techniques to precisely locate and quantify monocyte and macrophage subsets within the tissue sample.  
3. Review the patient's medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, can we expect a favorable response to Atezolizumab therapy? 1. Assess markers that indicate T cell exhaustion to evaluate how well cytotoxic T cells are functioning.  
2. Apply spatial analysis methods to accurately locate and measure different monocyte and macrophage populations in the tissue sample.  
3. Carefully review the patient’s medical history to determine their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"For this white male patient with bladder urothelial carcinoma, whose kidney biopsy-derived transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what can we infer about his likelihood of responding to atezolizumab therapy?","For this white male patient with bladder urothelial carcinoma, whose kidney biopsy-derived transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what can we infer about his likelihood of responding to atezolizumab therapy? 1. Evaluate markers of T cell exhaustion to determine the functional status of cytotoxic T cells.
2. Use spatial analysis techniques to precisely identify and quantify various monocyte and macrophage subsets within the tissue sample.
3. Thoroughly review the patient’s medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"In our white male patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these findings, can we anticipate a therapeutic response to Atezolizumab?","In our white male patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these findings, can we anticipate a therapeutic response to Atezolizumab? 1. Assess the expression of T cell exhaustion markers to evaluate the functionality of cytotoxic T cells.
2. Apply spatial analysis methods to accurately identify and quantify distinct monocyte and macrophage populations within the tissue specimen.
3. Review the patient’s medical history in detail to evaluate their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"I have a patient with bladder urothelial carcinoma with a tumor mutational burden of 3.0. Given the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy, what is the likelihood that this patient will respond to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma with a tumor mutational burden of 3.0. Given the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy, what is the likelihood that this patient will respond to atezolizumab therapy? 1. Evaluate the expression of exhaustion markers on T cells to determine the functional status of cytotoxic T cells.  
2. Utilize spatial analysis techniques to precisely identify and quantify the various monocyte and macrophage populations present in the tissue sample.  
3. Carefully review the patient's complete medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been analyzed via ureter biopsy transcriptomics and who has a tumor mutational burden of 10 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been analyzed via ureter biopsy transcriptomics and who has a tumor mutational burden of 10 mutations per megabase, what is the likelihood of a favorable response to Atezolizumab therapy? 1. Assess exhaustion marker expression on T cells to determine the functional capacity of cytotoxic T cells.  
2. Use spatial analysis methods to accurately identify and quantify the distinct monocyte and macrophage populations in the tissue sample.  
3. Review the patient’s complete medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"My Caucasian male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, and the tumor exhibits a TMB of 3.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy?","My Caucasian male patient with bladder urothelial carcinoma (BLCA) has a transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, and the tumor exhibits a TMB of 3.0. Based on these findings, can we anticipate a favorable response to Atezolizumab therapy? 1. Evaluate the expression of exhaustion markers on T cells to determine the functional status of cytotoxic T lymphocytes.  
2. Employ spatial analysis techniques to reliably identify and quantify the specific populations of monocytes and macrophages within the tissue sample.  
3. Examine the patient’s comprehensive medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The tumor's immune microenvironment has been profiled transcriptomically from a bladder biopsy, and the tumor mutational burden (TMB) is 3.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The tumor's immune microenvironment has been profiled transcriptomically from a bladder biopsy, and the tumor mutational burden (TMB) is 3.0. Based on these findings, is it likely that the patient will respond to Atezolizumab therapy? 1. Assess T cells for exhaustion markers to determine the functional status of cytotoxic T lymphocytes.  
2. Use spatial analysis methods to accurately locate and quantify monocyte and macrophage populations within the tissue sample.  
3. Review the patient’s full medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"For a Black/African American female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized through a lung biopsy and exhibits a tumor mutational burden of 11.0, does the current transcriptomic and mutational data support a favorable response to Atezolizumab therapy?","For a Black/African American female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized through a lung biopsy and exhibits a tumor mutational burden of 11.0, does the current transcriptomic and mutational data support a favorable response to Atezolizumab therapy? 1. Evaluate T cells for markers of exhaustion to determine how effectively cytotoxic T lymphocytes are functioning.  
2. Employ spatial analysis techniques to precisely identify and quantify monocyte and macrophage populations in the tissue sample.  
3. Conduct a comprehensive review of the patient's medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma, we have transcriptomic data from a lymph node biopsy of the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. Based on these findings, is Atezolizumab therapy likely to be effective?","In a Caucasian male patient with bladder urothelial carcinoma, we have transcriptomic data from a lymph node biopsy of the tumor immune microenvironment, but the tumor mutational burden (TMB) is unavailable. Based on these findings, is Atezolizumab therapy likely to be effective? 1. Assess T cells for exhaustion markers to determine the functional status of cytotoxic T lymphocytes.  
2. Utilize spatial analysis methods to accurately locate and quantify monocyte and macrophage populations in the tissue sample.  
3. Review the patient's complete medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from a liver biopsy is available, and his tumor mutational burden is not reported. Based on these findings, could the patient benefit from atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment from a liver biopsy is available, and his tumor mutational burden is not reported. Based on these findings, could the patient benefit from atezolizumab therapy? 1. Evaluate T cells for markers of exhaustion to assess the functional status of cytotoxic T lymphocytes.  
2. Apply spatial analysis techniques to precisely identify and quantify monocyte and macrophage populations within the tissue sample.  
3. Thoroughly review the patient’s full medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"I have a Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 26.0. A transcriptomic profile of her tumor immune microenvironment from a ureter biopsy is available. Based on this information, what is the likelihood of her responding to atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma and a tumor mutation burden of 26.0. A transcriptomic profile of her tumor immune microenvironment from a ureter biopsy is available. Based on this information, what is the likelihood of her responding to atezolizumab therapy? 1. Examine the T lymphocytes for exhaustion markers to evaluate the functional performance of cytotoxic T cells.  
2. Utilize spatial analysis methods to accurately locate and quantify monocyte and macrophage populations within the tissue specimen.  
3. Conduct a comprehensive review of the patient’s full medical history to assess their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy reveals a tumor immune microenvironment transcriptomic profile and a tumor mutational burden of 14.0, how likely is a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy reveals a tumor immune microenvironment transcriptomic profile and a tumor mutational burden of 14.0, how likely is a positive response to atezolizumab therapy? 1. Assess T lymphocytes for markers of exhaustion to determine the functional activity of cytotoxic T cells.
2. Apply spatial mapping techniques to precisely identify and measure monocyte and macrophage populations within the tissue sample.
3. Thoroughly review the patient’s complete medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment was performed on a lung biopsy and the tumor mutational burden is not available, what is the likelihood of response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment was performed on a lung biopsy and the tumor mutational burden is not available, what is the likelihood of response to Atezolizumab therapy? 1. Evaluate T lymphocytes for exhaustion markers to assess the functional status of cytotoxic T cells.  
2. Use spatial mapping techniques to accurately identify and quantify monocyte and macrophage populations within the tissue sample.  
3. Conduct a comprehensive review of the patient’s medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"In a Caucasian female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Given her tumor mutational burden of 4.0, what is the likelihood that she will respond to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Given her tumor mutational burden of 4.0, what is the likelihood that she will respond to atezolizumab therapy? 1. Assess T lymphocytes for the presence of exhaustion markers to determine the functional capacity of cytotoxic T cells.  
2. Apply spatial mapping methods to precisely locate and quantify monocyte and macrophage populations in the tissue sample.  
3. Perform a thorough review of the patient’s medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"We have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled using transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 3.0. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled using transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 3.0. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy? 1. Evaluate T lymphocytes for specific exhaustion markers to gauge the functional status of cytotoxic T cells.  
2. Utilize spatial mapping techniques to accurately identify and quantify monocyte and macrophage populations within the tissue.  
3. Conduct a detailed review of the patient’s medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 22.0, is there evidence to support a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 22.0, is there evidence to support a favorable response to atezolizumab therapy? 1. Assess T lymphocytes for markers of exhaustion to determine the functional capacity of cytotoxic T cells.  
2. Apply spatial mapping methods to precisely locate and measure populations of monocytes and macrophages within the tissue.  
3. Thoroughly review the patient’s medical history to evaluate their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,For a Caucasian male patient with biopsy-confirmed bladder urothelial carcinoma who has a transcriptomic profile of his tumor immune microenvironment—and with tumor mutational burden data currently unavailable—can we predict his likelihood of responding to atezolizumab therapy?,"For a Caucasian male patient with biopsy-confirmed bladder urothelial carcinoma who has a transcriptomic profile of his tumor immune microenvironment—and with tumor mutational burden data currently unavailable—can we predict his likelihood of responding to atezolizumab therapy? 1. Evaluate T lymphocytes for exhaustion markers to assess the functional capacity of cytotoxic T cells.  
2. Use spatial mapping techniques to accurately identify and quantify monocyte and macrophage populations within the tissue.  
3. Conduct a comprehensive review of the patient’s medical history to appraise their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 3.0, and for whom we have transcriptomic profiling data of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that she will respond to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 3.0, and for whom we have transcriptomic profiling data of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood that she will respond to Atezolizumab therapy? 1. Assess T lymphocytes for exhaustion markers to determine the functional status of cytotoxic T cells.  
2. Employ spatial mapping techniques to precisely identify and quantify monocyte and macrophage populations within the tissue.  
3. Review the patient’s complete medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his tumor mutation burden is 62.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of his tumor immune microenvironment from a kidney biopsy, and his tumor mutation burden is 62.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? 1. Evaluate T lymphocytes for exhaustion markers to determine the current functional status of cytotoxic T cells.  
2. Utilize spatial mapping techniques to accurately locate and quantify monocyte and macrophage populations within the tissue.  
3. Conduct a comprehensive review of the patient’s medical history to assess their response to the ongoing treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I have a patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profiling reveals insights into the immune microenvironment, and the tumor mutational burden is 14.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profiling reveals insights into the immune microenvironment, and the tumor mutational burden is 14.0. Based on these findings, can we expect a favorable response to Atezolizumab therapy? 1. Assess T lymphocytes for exhaustion markers to evaluate the functional status of cytotoxic T cells.  
2. Use spatial mapping techniques to precisely identify and quantify monocyte and macrophage populations in the tissue sample.  
3. Review the patient’s complete medical history to determine their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"Given a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 7.0 and transcriptomic profiling data from a lymph node biopsy of the tumor immune microenvironment, is Atezolizumab likely to be an effective treatment option?","Given a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 7.0 and transcriptomic profiling data from a lymph node biopsy of the tumor immune microenvironment, is Atezolizumab likely to be an effective treatment option? 1. Evaluate T lymphocytes for signs of exhaustion to determine the functional state of cytotoxic T cells.
2. Employ spatial mapping methods to accurately locate and quantify monocyte and macrophage populations within the tissue.
3. Review the patient’s full medical history to assess their response to the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"We have a patient with bladder urothelial carcinoma with a tumor mutation burden of 15.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Given these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy?","We have a patient with bladder urothelial carcinoma with a tumor mutation burden of 15.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Given these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy? 1. Assess the T lymphocytes for indicators of exhaustion to determine whether the cytotoxic T-cell function is compromised.  
2. Utilize spatial mapping techniques to precisely identify and quantify the distribution of monocyte and macrophage populations within the tissue.  
3. Conduct a comprehensive review of the patient’s medical history to evaluate their response to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and transcriptomic data from a kidney biopsy assessing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and transcriptomic data from a kidney biopsy assessing the tumor immune microenvironment, what is the likelihood of response to Atezolizumab therapy? 1. Evaluate T lymphocytes for signs of exhaustion to determine if their cytotoxic function may be compromised.  
2. Use spatial mapping techniques to accurately locate and measure the density of monocyte and macrophage populations within the tissue.  
3. Review the patient’s medical history thoroughly to assess how well they are responding to the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden value reported as ""nan,"" what is the likelihood that he will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden value reported as ""nan,"" what is the likelihood that he will respond to atezolizumab therapy? 1. Assess T lymphocytes for signs of functional exhaustion that could indicate reduced cytotoxic activity.  
2. Employ spatial mapping methods to accurately identify and quantify monocyte and macrophage populations within the tissue.  
3. Conduct a comprehensive review of the patient's medical history to evaluate the effectiveness of the current treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy has been completed, but the tumor mutation burden is not available. Given these results, is there evidence to support a likely response to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy has been completed, but the tumor mutation burden is not available. Given these results, is there evidence to support a likely response to atezolizumab therapy? 1. Evaluate the T lymphocytes for signs of exhaustion that may be impairing their ability to kill target cells.  
2. Use spatial mapping techniques to precisely identify and measure the monocyte and macrophage populations within the tissue.  
3. Review the patient’s medical history in detail to determine how effective the current treatment plan has been.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 24.0, would you anticipate a favorable response to Atezolizumab therapy based on these molecular findings?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 24.0, would you anticipate a favorable response to Atezolizumab therapy based on these molecular findings? 1. Assess the T lymphocytes for any signs of exhaustion that could compromise their cytotoxic function.
2. Employ spatial mapping techniques to accurately locate and quantify the monocyte and macrophage populations within the tissue.
3. Conduct a thorough review of the patient’s medical history to evaluate the effectiveness of the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA), and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden (TMB) data is not available. Based on this information, is it reasonable to expect a response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA), and we obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden (TMB) data is not available. Based on this information, is it reasonable to expect a response to Atezolizumab therapy? 1. Evaluate the T lymphocytes for indications of exhaustion that might impair their ability to effectively kill target cells.  
2. Utilize spatial mapping methods to precisely locate and quantify the distribution of monocyte and macrophage populations within the tissue.  
3. Review the patient’s medical history comprehensively to assess how well the current treatment regimen is working.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"I have a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. His tumor mutational burden (TMB) is 8.0. Based on this information, do you think he is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who underwent a ureter biopsy, and we have obtained a transcriptomic profile of his tumor immune microenvironment. His tumor mutational burden (TMB) is 8.0. Based on this information, do you think he is likely to respond to Atezolizumab therapy? 1. Assess T lymphocytes for exhaustion markers that may hinder their capacity to eliminate target cells effectively.  
2. Employ spatial mapping techniques to accurately identify and measure the presence and distribution of monocytes and macrophages within the tissue.  
3. Conduct a thorough review of the patient's medical history to evaluate the effectiveness of the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from his kidney biopsy indicates a tumor mutation burden (TMB) of 4.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from his kidney biopsy indicates a tumor mutation burden (TMB) of 4.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? 1. Evaluate the T lymphocytes for signs of exhaustion that might impair their ability to destroy target cells.  
2. Use spatial mapping methods to precisely locate and quantify monocytes and macrophages within the tissue.  
3. Review the patient’s medical history thoroughly to assess the effectiveness of the current treatment regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutation burden of 14.0, what is the likelihood that he will benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutation burden of 14.0, what is the likelihood that he will benefit from Atezolizumab therapy? 1. Assess the T lymphocytes for any signs of functional exhaustion that may hinder their ability to eliminate target cells.  
2. Employ spatial mapping techniques to accurately identify and quantify the monocytes and macrophages within the tissue.  
3. Conduct a comprehensive review of the patient’s medical history to evaluate the current treatment regimen’s effectiveness.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 5.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there an expectation of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, a tumor mutational burden of 5.0, and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, is there an expectation of a favorable response to Atezolizumab therapy? 1. Evaluate the T lymphocytes for any indications of functional exhaustion that might compromise their ability to destroy target cells.
2. Utilize spatial mapping methods to precisely locate and count the monocytes and macrophages within the tissue sample.
3. Thoroughly review the patient’s medical history to determine whether the current treatment regimen is effective.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutation burden of 10 mutations per megabase, what is the likelihood of response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutation burden of 10 mutations per megabase, what is the likelihood of response to Atezolizumab therapy? 1. Assess the T lymphocytes to determine if there is any evidence of functional exhaustion that may impair their capacity to eliminate target cells.

2. Employ spatial mapping techniques to accurately identify and quantify monocytes and macrophages in the tissue sample.

3. Carefully review the patient’s medical history to evaluate whether the current treatment plan is achieving the desired outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy and currently has an indeterminate tumor mutational burden, what is the likelihood that they will respond to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy and currently has an indeterminate tumor mutational burden, what is the likelihood that they will respond to atezolizumab therapy? 1. Evaluate the T lymphocytes for signs of functional exhaustion that might reduce their ability to eliminate target cells. 

2. Utilize spatial mapping techniques to accurately identify and quantify monocytes and macrophages in the tissue sample. 

3. Review the patient's medical history comprehensively to assess whether the current treatment plan is achieving its intended outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"I am managing a white male patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, but his tumor mutation burden is not available. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma. We have obtained a transcriptomic profile of his tumor immune microenvironment from a lymph node biopsy, but his tumor mutation burden is not available. Based on these data, what is the likelihood that he will respond to Atezolizumab therapy? 1. Assess T lymphocytes for any evidence of functional exhaustion that might impair their capacity to clear target cells.
2. Employ spatial mapping techniques to reliably locate and quantify monocytes and macrophages within the tissue sample.
3. Conduct a thorough review of the patient’s medical history to evaluate whether the current treatment regimen is meeting its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"I have a White male patient with bladder urothelial carcinoma and a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy. With a tumor mutational burden of 19.0, could Atezolizumab be an effective treatment option for this patient?","I have a White male patient with bladder urothelial carcinoma and a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy. With a tumor mutational burden of 19.0, could Atezolizumab be an effective treatment option for this patient? 1. Evaluate T lymphocytes for indications of functional exhaustion that could reduce their ability to eliminate target cells.  
2. Use spatial mapping techniques to accurately locate and count monocytes and macrophages within the tissue sample.  
3. Review the patient's full medical history comprehensively to determine if the current treatment regimen is achieving its intended therapeutic effects.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"I have a patient with bladder urothelial carcinoma who recently underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment. The tumor exhibits a TMB of 5.0. Based on these data, what is the likelihood of a response to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who recently underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment. The tumor exhibits a TMB of 5.0. Based on these data, what is the likelihood of a response to Atezolizumab therapy? 1. Assess the T lymphocytes to determine whether they exhibit signs of functional exhaustion, which could impair their ability to destroy target cells.  
2. Utilize spatial mapping methods to precisely identify and enumerate monocytes and macrophages present in the tissue sample.  
3. Thoroughly review the patient's complete medical history to evaluate whether the current treatment regimen is effectively meeting its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 2.0. Based on these findings, is she likely to respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 2.0. Based on these findings, is she likely to respond to Atezolizumab therapy? 1. Evaluate the T lymphocytes to determine if they show signs of functional exhaustion, which could reduce their ability to kill target cells.
2. Apply spatial mapping techniques to accurately identify and quantify monocytes and macrophages in the tissue sample.
3. Review the patient’s complete medical history to assess whether the current treatment regimen is achieving its therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0, can the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy help predict his response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0, can the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy help predict his response to Atezolizumab therapy? 1. Assess the T lymphocytes for any signs of functional exhaustion that might impair their cytotoxic activity.
2. Employ spatial mapping techniques to accurately locate and quantify monocytes and macrophages within the tissue sample.
3. Review the patient’s comprehensive medical history to evaluate whether the current treatment regimen is effectively meeting its therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained via nano biopsy and who has a tumor mutation burden of 17.0, what are the prospects for a positive response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained via nano biopsy and who has a tumor mutation burden of 17.0, what are the prospects for a positive response to Atezolizumab therapy? 1. Evaluate the T lymphocytes for indications of functional exhaustion that could reduce their cytotoxic efficacy.
2. Apply spatial mapping methods to precisely locate and measure the presence of monocytes and macrophages within the tissue.
3. Examine the patient’s complete medical history to determine if the current treatment plan is successfully achieving its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"We have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy is available, but the tumor mutational burden was not assessable (recorded as “nan”). Based on these molecular findings, is there an indication that the patient might respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy is available, but the tumor mutational burden was not assessable (recorded as “nan”). Based on these molecular findings, is there an indication that the patient might respond to Atezolizumab therapy? 1. Assess the T lymphocytes to determine if there are any signs of functional exhaustion that might impair their ability to kill target cells.  
2. Use spatial mapping techniques to accurately identify and quantify the distribution of monocytes and macrophages in the tissue sample.  
3. Review the patient’s full medical history to evaluate whether the current treatment strategy is meeting its therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"Does a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 6.0, have a likelihood of responding to atezolizumab therapy?","Does a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 6.0, have a likelihood of responding to atezolizumab therapy? 1. Evaluate T lymphocyte function for any indications of exhaustion that could compromise their cytotoxic activity.
2. Apply spatial mapping methods to precisely locate and quantify monocytes and macrophages within the tissue sample.
3. Analyze the patient’s comprehensive medical history to determine if the current treatment plan is achieving its intended therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"In a Caucasian female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 9.0, is a favorable response to Atezolizumab therapy anticipated?","In a Caucasian female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 9.0, is a favorable response to Atezolizumab therapy anticipated? 1. Assess T lymphocyte activity to detect any signs of exhaustion that might reduce their ability to kill target cells.  
2. Use spatial mapping techniques to accurately locate and count monocytes and macrophages in the tissue specimen.  
3. Review the patient’s complete medical history to evaluate whether the current treatment regimen is effectively meeting its intended outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"My patient is a white female with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, and her tumor mutational burden is 5.0. Based on these findings, is she likely to respond to atezolizumab therapy?","My patient is a white female with bladder urothelial carcinoma. We obtained a transcriptomic profile of her tumor immune microenvironment from a kidney biopsy, and her tumor mutational burden is 5.0. Based on these findings, is she likely to respond to atezolizumab therapy? 1. Evaluate T lymphocyte function to determine whether any signs of exhaustion are present that could impair their ability to eliminate target cells.
2. Implement spatial mapping techniques to precisely locate and quantify monocytes and macrophages within the tissue specimen.
3. Thoroughly review the patient’s medical history to assess if the current treatment regimen is achieving the intended clinical outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"A White male patient with bladder urothelial carcinoma has undergone transcriptomic analysis of the tumor immune microenvironment from a liver biopsy and presents with a tumor mutational burden (TMB) of 5.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","A White male patient with bladder urothelial carcinoma has undergone transcriptomic analysis of the tumor immune microenvironment from a liver biopsy and presents with a tumor mutational burden (TMB) of 5.0. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? 1. Assess the function of T lymphocytes for any indicators of exhaustion that might reduce their ability to effectively eliminate target cells.
2. Apply spatial mapping methods to accurately identify and quantify the presence of monocytes and macrophages in the tissue sample.
3. Conduct a comprehensive review of the patient’s medical history to evaluate whether the current treatment regimen is achieving its intended clinical benefits.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, and with the tumor mutational burden unavailable (nan), is Atezolizumab therapy likely to be effective?","For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, and with the tumor mutational burden unavailable (nan), is Atezolizumab therapy likely to be effective? 1. Evaluate T lymphocyte function for signs of exhaustion that could compromise their ability to effectively clear target cells.
2. Use spatial mapping techniques to precisely locate and measure monocytes and macrophages within the tissue sample.
3. Thoroughly review the patient’s medical history to determine if the current treatment plan is meeting its intended outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, with a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and an unavailable tumor mutational burden assessment, is there evidence to support a likely response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, with a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and an unavailable tumor mutational burden assessment, is there evidence to support a likely response to Atezolizumab therapy? 1. Assess T lymphocyte activity for potential signs of exhaustion that may diminish their effectiveness in clearing target cells.
2. Apply spatial mapping techniques to accurately identify and quantify monocytes and macrophages within the tissue sample.
3. Conduct a detailed review of the patient’s medical history to determine if the current treatment plan is achieving its desired outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood that he will respond to Atezolizumab therapy? 1. Evaluate the activity of T lymphocytes for any indications of exhaustion that could reduce their ability to clear target cells.  
2. Use spatial mapping techniques to accurately locate and quantify monocytes and macrophages within the tissue sample.  
3. Review the patient’s medical history in detail to determine whether the current treatment plan is effectively achieving its intended outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy transcriptomic profile of the immune microenvironment and a tumor mutation burden of 1.0. Based on this data, what is the likelihood of a positive response to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy transcriptomic profile of the immune microenvironment and a tumor mutation burden of 1.0. Based on this data, what is the likelihood of a positive response to atezolizumab therapy? 1. Assess T lymphocyte function to determine if any signs of cellular exhaustion are present that might compromise their ability to eliminate target cells.  
2. Employ spatial mapping techniques to precisely identify and enumerate monocytes and macrophages within the tissue sample.  
3. Thoroughly review the patient's medical history to evaluate whether the current treatment regimen is achieving its intended outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"Our white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor microenvironment from a bladder biopsy, although his tumor mutational burden (TMB) is not available. Based on these findings, how likely is he to respond to Atezolizumab therapy?","Our white male patient with bladder urothelial carcinoma has a transcriptomic profile of his tumor microenvironment from a bladder biopsy, although his tumor mutational burden (TMB) is not available. Based on these findings, how likely is he to respond to Atezolizumab therapy? 1. Evaluate the functional performance of T lymphocytes to identify any signs of exhaustion that may reduce their capacity to effectively eliminate target cells.
2. Use spatial mapping methods to accurately locate and count monocytes and macrophages in the tissue sample.
3. Conduct a comprehensive review of the patient's medical history to determine if the current treatment regimen is producing the desired outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on this information, can we expect a favorable response to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. We obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 6.0. Based on this information, can we expect a favorable response to atezolizumab therapy? 1. Assess the functional capacity of T lymphocytes, paying special attention to any signs of exhaustion that might compromise their ability to eliminate target cells.
2. Utilize spatial mapping techniques to accurately identify and quantify monocytes and macrophages within the tissue sample.
3. Conduct a thorough review of the patient's medical history to evaluate whether the current treatment regimen is achieving the intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For a Caucasian female patient with bladder urothelial carcinoma who has a tumor mutation burden of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma who has a tumor mutation burden of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to atezolizumab therapy? 1. Evaluate the performance of T lymphocytes, specifically checking for any indicators of cellular exhaustion that could reduce their capacity to eliminate target cells. 

2. Employ spatial mapping techniques to accurately locate and quantify monocytes and macrophages within the tissue sample.

3. Review the patient’s full medical history to determine whether the current treatment regimen is achieving the desired therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"I have a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 7.0 and available transcriptomic data of his tumor immune microenvironment. Based on these findings, is it likely that he will benefit from atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 7.0 and available transcriptomic data of his tumor immune microenvironment. Based on these findings, is it likely that he will benefit from atezolizumab therapy? 1. Assess T lymphocyte functionality by examining specific markers of cellular exhaustion that might impair their ability to eradicate target cells.

2. Use spatial mapping techniques to precisely identify and quantify monocytes and macrophages in the tissue sample.

3. Conduct a comprehensive review of the patient’s medical history to determine if the current treatment plan is effectively achieving the intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For my white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile (from a bladder biopsy) indicates a tumor mutational burden of 14.0 mutations per megabase. Given this information, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor transcriptomic profile (from a bladder biopsy) indicates a tumor mutational burden of 14.0 mutations per megabase. Given this information, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? 1. Evaluate T lymphocyte function by analyzing specific exhaustion markers that could compromise their capacity to eliminate target cells.  
2. Utilize spatial mapping techniques to accurately identify and measure the presence of monocytes and macrophages within the tissue sample.  
3. Thoroughly review the patient’s medical history to assess whether the current treatment plan is effectively achieving its intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 2.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is Atezolizumab likely to be effective?","For a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 2.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, is Atezolizumab likely to be effective? 1. Assess T cell functionality by examining markers of exhaustion that might impair their ability to clear target cells.  
2. Apply spatial mapping techniques to detect and quantify monocytes and macrophages within the tissue sample accurately.  
3. Conduct a comprehensive review of the patient’s medical history to determine if the ongoing treatment is meeting its therapeutic goals effectively.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these findings, is it reasonable to expect a response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy, and the tumor mutation burden is not available. Based on these findings, is it reasonable to expect a response to Atezolizumab therapy? 1. Evaluate T cell function by assessing markers of exhaustion that may limit their capacity to eliminate target cells.  
2. Use spatial mapping techniques to accurately identify and count monocytes and macrophages in the tissue sample.  
3. Review the patient's complete medical history to determine whether the current treatment is effectively achieving its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, given transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden reported as ""nan,"" what is the anticipated likelihood of response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, given transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden reported as ""nan,"" what is the anticipated likelihood of response to atezolizumab therapy? 1. Assess the functional capacity of T cells by evaluating exhaustion markers, which may compromise their ability to effectively target and eliminate diseased cells.  
2. Employ spatial mapping techniques to precisely locate and quantify monocytes and macrophages within the tissue sample.  
3. Thoroughly review the patient's complete medical history to confirm whether the current treatment regimen is meeting its intended therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 1.0, can the transcriptomic profile of the tumor immune microenvironment from a lung biopsy predict a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 1.0, can the transcriptomic profile of the tumor immune microenvironment from a lung biopsy predict a favorable response to atezolizumab therapy? 1. Evaluate T-cell functionality by assessing exhaustion markers that could impair their ability to effectively target and eliminate diseased cells.
2. Utilize spatial mapping techniques to accurately identify and quantify monocytes and macrophages present in the tissue sample.
3. Review the patient's complete medical history in detail to ensure that the current treatment regimen is achieving its intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, a TMB of 14, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, can we anticipate a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a TMB of 14, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, can we anticipate a favorable response to atezolizumab therapy? 1. Assess the functionality of T-cells by measuring specific exhaustion markers to determine if they may be underperforming in their ability to target abnormal cells.
2. Apply spatial mapping techniques to precisely locate and quantify monocytes and macrophages within the tissue sample.
3. Conduct an in-depth review of the patient’s complete medical history to verify that the current treatment regimen is delivering the expected therapeutic benefits.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"We have a Caucasian male patient with bladder urothelial carcinoma whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 14.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 14.0. Based on these findings, is it likely that he will respond to Atezolizumab therapy? 1. Evaluate T-cell function by measuring key exhaustion markers to determine if they are less effective at targeting abnormal cells.
2. Employ spatial mapping techniques to accurately locate and quantify monocytes and macrophages within the tissue sample.
3. Carefully review the patient’s full medical history to confirm that the current treatment plan is achieving the expected therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"In a Black/African American male patient with bladder urothelial carcinoma, a tumor mutational burden of 9.0, and a transcriptomic profile from a bladder biopsy detailing the tumor immune microenvironment, how likely is it that the patient will respond to atezolizumab therapy?","In a Black/African American male patient with bladder urothelial carcinoma, a tumor mutational burden of 9.0, and a transcriptomic profile from a bladder biopsy detailing the tumor immune microenvironment, how likely is it that the patient will respond to atezolizumab therapy? 1. Assess T-cell functionality by measuring key exhaustion markers to determine whether these cells have diminished ability to target abnormal cells.
2. Utilize spatial mapping techniques to accurately identify and quantify the presence of monocytes and macrophages within the tissue sample.
3. Review the patient’s comprehensive medical history to verify that the current treatment plan is producing the intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"I have a white male patient with bladder urothelial carcinoma (BLCA). Given the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, what is the likelihood that he would respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma (BLCA). Given the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 8.0, what is the likelihood that he would respond to atezolizumab therapy? 1. Evaluate T-cell functionality by measuring key exhaustion markers to determine if these cells are less effective in targeting abnormal cells.
2. Use spatial mapping techniques to precisely locate and quantify monocytes and macrophages in the tissue sample.
3. Review the patient’s complete medical history to confirm that the current treatment plan is achieving its intended therapeutic effects.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"In a white female patient with bladder urothelial carcinoma, a tumor mutational burden of 7.0, and transcriptomic profiling data available from a bladder biopsy, how predictive is this information for a favorable response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, a tumor mutational burden of 7.0, and transcriptomic profiling data available from a bladder biopsy, how predictive is this information for a favorable response to Atezolizumab therapy? 1. Assess T-cell performance by quantifying specific exhaustion markers to determine if these cells have reduced effectiveness against abnormal targets.

2. Apply spatial mapping techniques to accurately detect and quantify monocytes and macrophages within the tissue sample.

3. Review the patient’s complete medical history to verify that the current treatment regimen is delivering the intended therapeutic benefits.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"I have an Asian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden of 4.0. Based on these findings, would you expect her to respond to atezolizumab therapy?","I have an Asian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment, obtained from a kidney biopsy, revealed a tumor mutational burden of 4.0. Based on these findings, would you expect her to respond to atezolizumab therapy? 1. Evaluate T-cell function by measuring specific exhaustion markers to determine if these cells are compromised in their ability to target abnormal cells.

2. Utilize spatial mapping methods to accurately identify and quantify monocytes and macrophages within the tissue sample.

3. Examine the patient’s full medical history to confirm that the current treatment plan is effectively achieving the desired therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"I have a white male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 7.0. I also have transcriptomic profiling data of the tumor immune microenvironment obtained from a kidney biopsy. Based on these findings, could Atezolizumab therapy be effective for this patient?","I have a white male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 7.0. I also have transcriptomic profiling data of the tumor immune microenvironment obtained from a kidney biopsy. Based on these findings, could Atezolizumab therapy be effective for this patient? 1. Assess T-cell function by quantifying specific exhaustion markers to determine whether these cells have a reduced capacity to target abnormal cells.
2. Employ spatial mapping techniques to precisely locate and count monocytes and macrophages within the tissue sample.
3. Review the patient's comprehensive medical history to verify that the existing treatment plan is effectively achieving the intended therapeutic outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the TMB value is not available. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the TMB value is not available. Based on this data, what is the likelihood that the patient will respond to Atezolizumab therapy? 1. Evaluate T-cell performance by measuring specific exhaustion markers to determine if these cells exhibit an impaired ability to eliminate abnormal cells.
2. Utilize spatial mapping techniques to accurately locate and quantify monocytes and macrophages in the tissue sample.
3. Carefully review the patient's comprehensive medical history to ensure that the current treatment regimen is meeting its targeted therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 5.0 and available transcriptomic data from his bladder biopsy detailing the tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden of 5.0 and available transcriptomic data from his bladder biopsy detailing the tumor immune microenvironment. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? 1. Assess T-cell functionality by quantifying markers of exhaustion to determine whether these cells have a reduced capacity to eliminate abnormal cells.
2. Use spatial mapping techniques to accurately identify and count monocytes and macrophages present in the tissue sample.
3. Review the patient’s full medical history in detail to verify that the current treatment plan is effectively achieving its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"I have a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 7.0. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, do you anticipate that she would respond favorably to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 7.0. We have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Based on these findings, do you anticipate that she would respond favorably to atezolizumab therapy? 1. Evaluate T-cell function by measuring exhaustion markers, which will help determine if these cells are less effective at eliminating abnormal cells.
2. Employ spatial mapping techniques to precisely locate and quantify monocytes and macrophages in the tissue sample.
3. Conduct a thorough review of the patient’s complete medical history to confirm that the current treatment plan is meeting its therapeutic objectives.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized via transcriptomic profiling and who has a tumor mutational burden of 10.0, how likely is he to respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized via transcriptomic profiling and who has a tumor mutational burden of 10.0, how likely is he to respond to Atezolizumab therapy? 1. Assess T-cell functionality by measuring exhaustion markers to determine if these cells are compromised in their ability to combat abnormal cells.
2. Use spatial mapping techniques to accurately identify and quantify monocytes and macrophages in the tissue sample.
3. Review the patient’s complete medical history in detail to ensure that the current treatment plan is effectively achieving its therapeutic goals.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
